A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma

This is a pre print version of the following article:

Original Citation:

Availability:

This version is available http://hdl.handle.net/2318/1848740 since 2022-03-11T15:33:58Z

Published version:

DOI:10.1016/j.critrevonc.2022.103639

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)
**Introduction**
Advanced stage malignant mesothelioma (asMM) patients have poor prognosis. Several trials investigated the role of programmed cell death protein-1 (PD-1) and its ligand 1 (PD-L1) immune checkpoint inhibitors (ICIs) in pre-treated asMM.

**Methods**
A systematic review of the literature of clinical trials testing single-agent anti PD-1/PD-L1 ICIs in pre-treated asMM was performed. Objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS) and overall survival (OS) data were extracted. The predictive role of PD-L1 was assessed.

**Results**
We selected 13 studies including 888 patients. ORR and DCR were 18.1% (95%
Confidence interval [CI] 13.9-22.8%) and 55.4% (95% CI: 48.1-62.5%), respectively. Median PFS and OS ranged from 2.1 to 5.9 and from 6.7 to 20.9 months, respectively. ORR according to PD-L1 was 27.0% (95% CI: 18.7-36.2%).

Conclusions

Anti-PD-(L)1 ICIs might be considered a treatment option for chemotherapy-resistant asMM, even if reliable predictive factors are still lacking.
Dear Sir,

We would like to submit a new version of our manuscript "A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma" for publication on Critical Reviews in Oncology/Hematology. This systematic review and meta-analysis aims at elucidating the role of anti PD-1/PD-L1 monoclonal antibodies in pre-treated advanced malignant mesothelioma in terms of response rate (RR) and disease control rate (DCR). We found that these agents could led 18.1% RR and 55.4% DCR, with possibly higher activity in PD-L1 positive patients. Despite immune checkpoint inhibitors combinations in the first-line setting are changing treatment approach in non-epithelioid tumors, patients with epithelioid mesothelioma seem derive less benefit from this approach. Therefore, it is worth to investigate the activity of single agent anti PD1/PD-L1 agents chemotherapy pre-treated patients. Indeed, we think that our analysis could add more data in this evolving clinical scenario. According to reviewer’s comments we updated our original work submitted on December 2020, by including new published studies. We also modified the discussion section by highlighting novel evidences from recently published and presented trials. We hope that this works would we considered of interest for the readers of Critical Reviews in Oncology/Hematology.

This manuscript is not under consideration for publication to other journals.

Best regards

Paolo Bironzo, MD
Assistant Professor
Department of Oncology
University of Torino
Regione Gonzole 10, 10043, Orbassano, Italy
paolo.bironzo@unito.it
Dear Sir,

We would like to submit a new version of our manuscript "A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma" for publication on Critical Reviews in Oncology/Hematology. This systematic review and meta-analysis aims at elucidating the role of anti PD-1/PD-L1 monoclonal antibodies in pre-treated advanced malignant mesothelioma in terms of response rate (RR) and disease control rate (DCR). We found that these agents could lead 18.1% RR and 55.4% DCR, with possibly higher activity in PD-L1 positive patients. Despite immune checkpoint inhibitors combinations in the first-line setting are changing treatment approach in non-epithelioid tumors, patients with epithelioid mesothelioma seem derive less benefit from this approach. Therefore, it is worth to investigate the activity of single agent anti PD1/PD-L1 agents chemotherapy pre-treated patients. Indeed, we think that our analysis could add more data in this evolving clinical scenario. According to reviewer’s comments we updated our original work submitted on December 2020, by including new published studies. We also modified the discussion section by highlighting novel evidences from recently published and presented trials. We hope that this works would we considered of interest for the readers of Critical Reviews in Oncology/Hematology.

This manuscript is not under consideration for publication to other journals.

Best regards

Paolo Bironzo, MD
Assistant Professor
Department of Oncology
University of Torino
Regione Gonzole 10, 10043, Orbassano, Italy
paolo.bironzo@unito.it
Dear Sir,

according to reviewers’ comments we revised our manuscript. Moreover, we updated our meta-analysis by including 3 more studies that have been published in the meantime. The attached manuscript has all changes tracked. The following reviewers’ comments have been addressed:

- “Albeit out of the scope of this metanalysis ("Search was made on Pubmed/Medline and Cochrane library on September 13th, 2020"), the results of the recently published CONFIRM trial (Fennell et al. Lancet Oncol 2021) should be included, at least, in the Discussion. Similarly, the results of the recently published RAMES trial should be discussed (Pinto C, et al. Lancet Oncol 2021)”. We thank reviewer for this valuable comment. We updated our meta-analysis by including CONFIRM trial along with other 2 novel studies. Moreover, we update previous selected series by retrieving data from more recent publications. CONFIRM results were also included in the introduction. We also discussed RAMES trial in the discussion section of the manuscript.

- “In the Discussion, the authors can more extensively explain the context of pretreated MPM, reporting in more details the outcomes obtainable with single agent chemotherapy (see for example Petrelli F, et al. Respir Med. 2018). This could be useful for readers less familiar with the topic”. We thank the reviewer for his suggestion. We modified the discussion section by including the suggested reference as well as data from the VIM phase 2 trial presented at 2021 ASCO Annual Meeting.

- “Ref. 32 can be updated with the results of the full paper, recently published on Cancer Discovery (doi: 10.1158/2159-8290.CD-21-0407)”. We thank the reviewer for this comment. We updated the reference accordingly.

- “KEYNOTE-158 data can be updated (Yap TA, et al. Lancet Respir Med. 2021)”. We appreciated reviewer’s comment. We update data from KEYNOTE-158 in our work.

- “Recent studies showed that PD-L1 expression has a prognostic role in MPM (Brcic L, et al. Transl Lung Cancer Res. 2021; Rrapaj E, et al. Pathology. 2021)”. We really appreciated this comment. We updated our discussion by pointing out such data.

- “Quality of the images and graphical abstract is poor. Please reupload the relative files in a higher quality format”. We thank reviewer for this comment. We uploaded images with higher quality.
A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma

Marco Tagliamento\textsuperscript{a,b}* , Paolo Bironzo\textsuperscript{c}* , Hubert Curcio\textsuperscript{d} , Emmanuele De Luca\textsuperscript{e} , Daniele Pignataro\textsuperscript{f} , Simonetta G. Rapetti\textsuperscript{c} , Marco Audisio\textsuperscript{c} , Valentina Bertaglia\textsuperscript{c} , Chiara Paratore\textsuperscript{c} , Maristella Bungaro\textsuperscript{c} , Emanuela Olmetto\textsuperscript{c} , Elisa Artusio\textsuperscript{c} , Maria Lucia Reale\textsuperscript{f} , Clizia Zichi\textsuperscript{e} , Enrica Capelletto\textsuperscript{c} , Simona Carnio\textsuperscript{c} , Lucio Buffoni\textsuperscript{g} , Francesco Passiglia\textsuperscript{c} , Silvia Novello\textsuperscript{c} , Giorgio Vittorio Scagliotti\textsuperscript{c} , Massimo Di Maio\textsuperscript{e}

a) Department of Internal Medicine and Medical Specialties (Di.M.I.), IRCCS Ospedale Policlinico San Martino, University of Genova, Largo Rosanna Benzi 10, 16132, Genova (Italy)
b) Cancer Medicine Department, Institut Gustave Roussy, 114 Rue Edouard Vaillant, 94805 Villejuif (France)
c) Department of Oncology, AOU San Luigi Gonzaga, University of Torino, Regione Gonzole 10, 10043, Orbassano (Italy)
d) Oncology Department, Centre Francois Baclesse, 3 Avenue Général Harris, Caen (France)
e) Department of Oncology, AOU Ordine Mauriziano, University of Torino, Largo Filippo Turati 62, 10128, Torino (Italy)
f) Oncology Unit, Ospedale Cardinal Massaia, Corso Dante Alighieri 202, 14100, Asti (Italy)
g) Oncology Unit, Humanitas Gradenigo Hospital, Corso Regina Margherita 8, 10153, Torino (Italy)

*Both Authors contributed equally to this work

Corresponding author
Paolo Bironzo
Department of Oncology, University of Turin, AOU San Luigi Gonzaga
Regione Gonzole 10, 10043, Orbassano (Italy)
Marco Tagliamento
Marco Tagliamento is a Medical Oncologist, PhD Student in Translational Oncology at the University of Genova (Italy) and Research Fellow at Gustave Roussy (Villejuif, France). He is involved as a researcher in clinical and translational studies in the field of thoracic malignancies. He is member of the European Organization for Research and Treatment of Cancer (EORTC) Lung Cancer Group.

Paolo Bironzo
Paolo Bironzo, MD, PhD, is assistant professor at the Department of Oncology of the University of Turin. His main research areas are thoracic tumours, especially lung cancer and pleural mesothelioma. He is a member of the European Organisation for the Research and Treatment of Cancer (EORTC) Lung Cancer Group Board and scientific secretary of the Italian Association of Medical Oncology (AIOM) Clinical Practice Guidelines. He is actively involved in clinical and translational research, including international collaborations, mainly on thoracic tumors. He is author and co-author of several works in peer-reviewed journals. He is member of the Italian Association of Medical Oncology (AIOM), International Association for the Study of Lung Cancer (IASLC), and European Society of Medical Oncology (ESMO).

Hubert Curcio
Hubert Curcio, MD, is Assistant Professor of Medical Oncology at the University of Caen, France. He is consultant in the Thoracic and Urologic Unit of the Department of Medical Oncology and co-head of the Molecular Tumor Board at the Centre Francois Baclesse Comprehensive Cancer Center. He is a member of the European Society of Medical Oncology (ESMO).

Emmanuele De Luca
Emmanuele De Luca is a Medical Oncologist at Humanitas Gradenigo, Turin, since February 2019. On 22/07/2013 he graduated from the University of Catania with a thesis entitled "Role of the ATP7A gene in predicting the efficacy of therapy with platinum derivatives in patients with malignant pleural mesothelioma". On December 2019 he specialized in Medical Oncology at the University of Turin the thesis: "Systematic review and meta-analysis of the literature of the efficacy of immune checkpoint inhibitors in elderly patients with advanced solid cancer: the IMAGE (IMmunotherapy and AGE) study”. His special interests are clinical and preclinical research in thoracic and genitourinary tumors as well as melanoma. He participated as a speaker at numerous conferences and have been involved in the writing of several thoracic oncology publications, collaborating in the drafting of guidelines for the Oncological Network of Piedmont and Valle D’Aosta.

Daniele Pignataro
Daniele Pignataro, MD, is a medical oncologist at Cardinal Massaia Hospital, Asti (Italy). His clinical activity is focused on the management of patients with thoracic tumors. His research interest is mainly focused on oncogene-addicted NSCLC and targeted therapies.

Simonetta G. Rapetti
Simonetta G. Rapetti, MD, is a pulmonologist at S. Luigi Gonzaga University Hospital, Orbassano (Italy). Her clinical activity is mainly focused on clinical management of patients affected by thoracic tumors. She is co-investigator of several clinical trials in thoracic malignancies. She is also involved in prevention campaigns on smoking-related illnesses, including lung cancer.

Marco Audisio
Marco Audisio, MD, is a fellow in medical oncology at the University of Torino (Italy). He graduated in Medicine at the University of Torino. He is involved in clinical management as well as research in solid tumors.

Valentina Bertaglia

Valentina Bertaglia is a consultant in Medical Oncology in the Oncology Department at San Luigi Hospital in Orbassano, University of Turin. In 2009, she graduated in Medicine and Surgery from the University of Turin. In 2015 she completed her specialist training in Medical Oncology and, in 2019, the PhD programme in Experimental Medicine and Therapy at the University of Turin. During her specialist training she worked as a Clinical Research Fellow with the lung and melanoma team at The Christie in Manchester, UK. She is specialised in the treatment of thoracic malignancies, including non-small cell lung cancer, small cell lung cancer, thymoma, thymic carcinoma and mesothelioma. She is involved as co-investigator in many international and national clinical trials evaluating new approaches for the diagnosis and treatment of lung cancer. She is a member of the European Societies for Medical Oncology (ESMO) and Italian Association of Medical Oncology (AIOM).

Chiara Paratore

Chiara Paratore, born in Catania on 22nd of April 1992. She graduated at medical school in 2016 with a degree score of 110 cum laude. She is a senior fellow in Medical Oncology at San Luigi Gonzaga Hospital of Orbassano, University of Turin (Italy). Her main area of research is thoracic oncology, with a focus on NSCLC and mesothelioma.

Maristella Bungaro

Maristella Bungaro is a senior fellow in Medical Oncology at the University of Torino, Italy. She graduated in medicine at the University of Bari, Italy. Her main research interests include NSCLC, especially oncogene-addicted tumors, and pleural mesothelioma.

Emanuela Olmetto

Emanuela Olmetto, MD, is a Radiation Oncologist at the Radiotherapy Unit of AOU Careggi of Florence (Italy). She worked from 2019 to 2022 at the AOU San Luigi Gonzaga of Orbassano (Italy), dealing with clinical trials concerning thoracic malignancies. She participated in national and international clinical studies promoting research on lung cancer.

Elisa Artusio

Elisa Artusio, MD, is a Medical Oncologist at San Luigi Gonzaga Hospital. She graduated at the University of Torino in 1994 and qualified as specialist in Medical Oncology in 1999. She worked as oncologist at Valdese Hospital in Torino from 1999 to 2014. From 2014 she works as Medical Oncologist at S. Luigi Gonzaga Hospital in Orbassano, Italy, where she is involved in clinical management of patients with thoracic malignancies. Her research experiences include: an internship at the Laboratory of Neurophysiology at the Department of Human Anatomy and Physiology of the University of Torino; post-graduate student at the Research Laboratory of Molecular and Cellular Biology, Department of Clinical Physiopathology, University of Torino; postdoctoral fellowship at the Monitoring & Cellular Products Laboratory, Department of Pathology, University of Pittsburgh Cancer Institute. USA. Her research interests include thoracic tumors and hereditary cancer syndromes.
Maria Lucia Reale
Dr. Maria Lucia Reale, MD, is a research fellow in thoracic oncology at the San Luigi Hospital. She graduated in Medicine at the University of Perugia in 2014 and obtained specialization in Medical Oncology in 2020 at the University of Turin. Her research interests include gender differences in lung cancer, quality of life evaluation, translational and clinical applied research on oncogene-addicted lung cancers and their mechanisms of acquired resistances to targeted therapies. She is member of different scientific societies (AIOM, ASCO, ESMO, IASLC). She is Member of the board directors of the no-profit European Association WALCE (Women Against Lung Cancer in Europe).

Clizia Zichi
Clizia Zichi is a 34-years old Medical Oncologist, working in Turin, at Mauriziano Hospital. She graduated in October 2013 at the University of Turin and then completed the Oncology training speciality course in December 2019. Now she deals with gastrointestinal and neuroendocrine cancers, with a special interest in thyroid cancers.

Enrica Capelletto
Enrica Capelletto, MD, is a pulmonologist at San Luigi Gonzaga Hospital. She is also a PhD student in Biomedical Sciences and Oncology at the University of Torino (Italy). Her main research interest is the prevention and treatment of thoracic tumors. She is actively involved in clinical research on thoracic tumors. She is author and co-author of several publication in peer-reviewed journals.

Simona Carnio
Simona Carnio, MD, is a medical oncologist at San Luigi Gonzaga Hospital, Orbassano (Italy). She is actively involved in clinical research and patients care. Her main research interests are thoracic tumors, patients quality of life and treatment toxicity management. She is scientific secretary for the Italian Association of Medical Oncology (AIOM) Clinical Practice Guidelines on Cancer Survivorship. She is author of several publications on indexed journals.

Lucio Buffoni
Lucio Buffoni has been an Oncologist since 2004. Since then, he always dealt with thoracic pathology including both lung cancer and tumors of the thymus and pleura. He always carried out his activity as an oncologist at reference hospitals for the diagnosis and treatment of cancer and, specifically, his main interest has always fallen on neoplasms of the thoracic district. The experience gained in these excellent structures allowed him to hold responsibility positions at the head of working groups dedicated to thoracic tumors. He was also responsible for the drafting and subsequent application of courses dedicated to the diagnosis and treatment of lung and pleural cancers. In these hospitals, he took part in research activities by participating in numerous national and international clinical trials. He also participated both as first author and as co-author in the publication of about 30 articles in international scientific peer-reviewed journals.

Francesco Passiglia
Francesco Passiglia, MD, PhD, is Associate Professor of Medical Oncology at the Department of Oncology of the University of Turin, Italy. He is consultant at the Thoracic Oncology Unit of San
Luigi Hospital, Orbassano (Turin). Since October 2019 he is the scientific secretary of the Italian Association of Medical Oncology (AIOM) Lung Cancer Clinical Practice Guidelines. He is member of international scientific societies including the American Society of Clinical Oncology (ASCO), the European Society of Medical Oncology (ESMO), the International Association for the Study of Lung Cancer (IASLC). He is author of about 90 publications in peer-reviewed journals.

**Silvia Novello**

Silvia Novello, MD, PhD is Full Professor of Medical Oncology in the Oncology Department at San Luigi Hospital in Orbassano, Italy, part of the University of Turin. She earned her medical degree and completed the postgraduate training in Respiratory Medicine and Medical Oncology at the University of Turin and partially at the Institut Gustave Roussy, in France. Currently, she is head of the Thoracic Oncology Unit at the San Luigi Hospital, Orbassano (Turin), where she also tutors medical students and Postgraduate students in Respiratory Medicine and Medical Oncology and Deputy Director of the Oncology Dept. Prof. Novello’s research interests include thoracic malignancies, primary prevention, gender differences in lung cancer, basic, translational and clinical applied research on lung cancer and mesothelioma, including pharmacogenomics. She is involved as PI in many International and national controlled clinical trials evaluating new approaches in diagnosis and lung cancer therapy. From July 2012 until 2016, Prof Novello has been a Member of the Board of Directors of the International Association for the Study of Lung Cancer and since October 2016 Member of the Board of Directors of the Italian Association of Medical Oncology, past Secretary and now part of the EORTC Lung Cancer Group and member of several scientific societies including the American Society of Clinical Oncology, American Thoracic Society and the European Society of Medical Oncology. Currently, she is the President of WALCE (Women Against Lung Cancer in Europe), a non profit European Association founded in 2006 in Turin, Italy, part of the scientific Committee of LuCe (Lung cancer Europe) and also member of the Scientific Committee of Bonnie J Addario Lung Cancer Foundation and Member of the Scientific Committee of ICAPEM (Investigación sobre Cáncer de Pulmón en Mujeres). She is the author or co-author of over 150 publications in peer-reviewed journals.

**Giorgio V. Scagliotti**

Prof. Scagliotti is Professor of Oncology at the University of Torino and former president of the International Association for the Study of Lung Cancer. He earned his medical degree and completed the postgraduate training in Respiratory Medicine, Internal Medicine, and Medical Oncology at the University of Torino. He is chief of the Medical Oncology Division at the S. Luigi Hospital, Orbassano (Torino).

**Massimo Di Maio**
Massimo Di Maio is associate professor of Medical Oncology at Department of Oncology, University of Turin, Italy, since 2014, and director of Medical Oncology at Mauriziano Hospital, Turin, since 2016. In 1999, he obtained degree *cum laude* in Medicine and Surgery at the University of Napoli “Federico II”, Italy. Four years later, in 2003, he graduated from the Specialty School in Oncology at the same University. From 2000 to 2006 and from 2008 to 2014 he worked at the Clinical Trials Unit of the National Cancer Institute “G.Pascale” Foundation, in Naples, Italy, where he was involved in the planning, conducting and analysis of clinical trials. His main areas of interest are: methodology of clinical trials in oncology, conduction of meta-analyses based on individual patients’ data, patient-reported outcomes in clinical research and in clinical practice. Prof Di Maio has been invited as speaker at many national and international meetings and has authored more than 340 publications in international peer-reviewed journals (H-Index November 2021: 45 according to Scopus, 45 according to Web of Science). Additionally, Prof. Di Maio is an active member of the Associazione Italiana di Oncologia Medica (Italian Society of Medical Oncology, AIOM) and the European Society of Medical Oncology (ESMO). Between 2009 and 2013, Prof. Di Maio acted as national coordinator of the AIOM Young Oncologists Working Group. Between 2013 and 2017, he was councillor (member of the National Board) of AIOM. Since October 2019, he is AIOM National Secretary.
Abstract

Introduction
Advanced stage malignant mesothelioma (asMM) patients have poor prognosis. Several trials investigated the role of programmed cell death protein-1 (PD-1) and its ligand 1 (PD-L1) immune checkpoint inhibitors (ICIs) in pre-treated asMM.

Methods
A systematic review of the literature of clinical trials testing single-agent anti PD-1/PD-L1 ICIs in pre-treated asMM was performed. Objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS) and overall survival (OS) data were extracted. The predictive role of PD-L1 was assessed.

Results
We selected 10 studies including 497 patients. ORR and DCR were 20.1% (95% confidence interval [CI] 16.8-23.9) and 54.6% (95% CI: 50.2-59.0), respectively. Median PFS and OS ranged from 2.5 to 6.1 and from 6.36 to 20.9 months, respectively. ORR according to PD-L1 expression ranged from 19% to 55.5%.

Conclusions
Anti-PD-(L)1 ICIs might be considered a treatment option for chemotherapy-resistant asMM, even if reliable predictive factors are still lacking.

Keywords
Mesothelioma; immune checkpoint inhibitors; nivolumab; pembrolizumab; avelumab

Abbreviations
MM: malignant mesothelioma
OS: overall survival
PFS: progression-free survival
ICls: immune checkpoint inhibitors
CTLA-4: cytotoxic T-lymphocyte antigen-4
PD-1: programmed cell death protein-1
PD-L1: programmed death-ligand 1
asMM: advanced stage malignant mesothelioma
mAbs: monoclonal antibodies
ASCO: American Society of Clinical Oncology
ESMO: European Society of Medical Oncology
IASLC: International Association for the Study of Lung Cancer
ELCC: European Lung Cancer Congress
HR: hazard ratio
CI: confidence interval
ORR: objective response rate
FDA: Food and Drug Administration
EMA: European Medicines Agency
q2w: every two weeks
q3w: every three weeks
ECOG: Eastern Cooperative Oncology Group
PS: performance status
IHC: immunohistochemistry
DoT: duration of treatment
RECIST: Response Evaluation Criteria in Solid Tumours
PD-L1+: PD-L1 positive
PD-L1-: PD-L1 negative
MPM: malignant pleural mesothelioma
mRECIST: modified RECIST
iRECIST: immune RECIST
DoR: duration of response
RR: response rate
PR: partial response
SD: stable disease
BAP1: BRCA1 associated protein 1
CAR-T: chimeric antigen receptor T-cell
1. Introduction

Malignant mesothelioma (MM) is a rare and aggressive tumour of mesothelial surfaces. Asbestos exposure is the main risk factor, even if this neoplasm can occur in non-exposed subjects and rarely can be due to germline mutations.\(^1\) The combination of platinum and pemetrexed is the standard systemic first-line treatment, providing a small although significant survival benefit as compared to platinum alone, and better symptom control.\(^2\) Recently, in one randomized study the addition of bevacizumab improved progression-free and overall survival (PFS and OS) as compared to chemotherapy alone.\(^3\) Overall clinical results are still modest, claiming for novel approaches to significantly ameliorate the survival of MM patients. In the last few years, immune checkpoint inhibitors (ICIs) radically changed treatment paradigm of many solid tumours. While cytotoxic T-lymphocyte antigen-4 (CTLA-4) directed agents did not confer any benefit in advanced MM,\(^4\) several trials and case-series suggest that programmed cell death protein-1 (PD-1) and programmed death-ligand 1 (PD-L1) antagonists may increase survival in pre-treated advanced stage MM (asMM) patients.\(^5\) However, such results are still debated because the only randomized trial did not show survival differences between pembrolizumab and single agent chemotherapy. To this end, we performed a systematic review and meta-analysis to define the activity and efficacy of PD-1/PD-L1 monoclonal antibodies (mAbs) in pre-treated asMM patients.

2. Material and Methods

2.1 Trial identification criteria

We identified all clinical trials testing ICIs in pre-treated asMM as single-agent in single-arm as well as multi-arm studies. The following Mesh terms were used: “mesothelioma”, “mesothelioma, malignant”, “atezolizumab”, “avelumab”, “durvalumab”, “nivolumab”, “pembrolizumab”. Search was made on Pubmed/Medline and Cochrane library on September 13\(^{th}\), 2020. Papers published in peer-reviewed journals and in English language were selected. We also searched proceedings of major International meetings such as American Society of Clinical Oncology- ASCO annual meetings, European Society of Medical Oncology- ESMO annual meetings, International Association for the Study of Lung Cancer- IASLC World Conferences on Lung Cancer, European Lung Cancer Congress-ELCC from 2014 onwards for relevant abstracts. When more than one report of the same study was available, the most recent data (with longer follow-up and/or higher number of patients) were considered (Figure 1).
2.2 Aims of the meta-analysis

- (i) To evaluate the activity of single-agent PD-1/PD-L1 directed ICIs in chemotherapy pre-treated asMM in terms of objective response rate (ORR) and disease control rate (DCR);
- (ii) To evaluate the efficacy of single-agent PD-1/PD-L1 directed ICIs in chemotherapy pre-treated asMM in terms of PFS and OS;
- (iii) To explore the potential role of PD-L1 expression as a predictive marker of activity. For this aim, the ORR and DCR analyses were repeated in the subgroup of patients included, within each trial, in the highest category of PD-L1 expression (even if with heterogeneous methods and cut-offs).

2.3 Data extraction for the meta-analysis

The following data were extracted from each study: (a) first author, phase of the study, and year of publication; (b) type of ICIs agent and number of patients assigned to the experimental treatment; (c) percentage of patients treated in second-line; (d) site of MM (pleural vs peritoneal vs others) and histology; (e) median follow-up and range; (f) ORR (number of patients obtaining objective response) in the whole study population and in the “PD-L1 high” subpopulation; in the randomized trial, ORR was collected for both treatment arms in order to calculate odds ratio; (g) DCR (number of patients obtaining objective response or disease stabilization) in the study population and in the “PD-L1 high” subpopulation; in the randomized trial, DCR was collected for both treatment arms in order to calculate odds ratio; (g) median PFS and median OS; in the randomized trial, hazard ratio (HR) and 95% confidence interval (CI) of experimental treatment compared to control arm, in the intention to treat population, were collected.

To obtain a quantitative measure of the degree of heterogeneity among studies included in the analysis, the Higgins I² index was computed. The likelihood of publication bias was assessed by both Egger’s and Begg’s tests. The MedCalc® Statistical Software version 19.6 (MedCalc Software Ltd, Ostend, Belgium; https://www.medcalc.org; 2020) was used for statistical analyses.

3. Results

3.1 Systematic review of the literature

3.1.1 Atezolizumab
No results from clinical trials evaluating the anti PD-L1 mAb atezolizumab in pre-treated asMM were found. However, a single-arm phase trial with atezolizumab in this population is ongoing [NCT 03786419].

3.1.2 Avelumab

Avelumab, a humanized anti-PD-L1 IgG1 mAb, has been evaluated in MM within the phase Ib JAVELIN trial. Fifty-three patients with unresectable pre-treated MM received avelumab 10 mg/Kg every two weeks (q2w). Median age was 67 years (range 32-84), and median number of previous lines was 2 (range 1-8). Thirty-two patients (60%) were male, and 39 (74%) had an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 1. Most patients had epithelioid histology (n:43, 81%). PD-L1 expression, evaluated with Dako PD-L1 immunohistochemistry (IHC) 73-10 pharmDx, was ≥1% in 21 patients (40%), negative in 22 patients (42%), not evaluable in 10 (19%). High PD-L1 expression (≥5% of positive tumour cells) was reported in 16 patients (30%), while 27 (51%) had a low/negative expression. The median duration of treatment (DoT) was 2.8 months (range 0.9-28.1), with a median of 6 delivered doses (range 2-59). At a median follow-up of 24.8 months (range 16.8-27.8), the ORR (by Response Evaluation Criteria in Solid Tumours- RECIST 1.1) was 9% (95% CI: 3.1-20.7) and the DCR was 58% (n:31). Median PFS and OS were 4.1 (95% CI: 1.4-6.2) and 10.7 (95% CI: 6.4-20.2) months, respectively. ORR was higher in PD-L1 high (19%, 3 out of 16 patients; 95% CI: 4.0-45.6) than in low/negative patients (7%, 2 out of 27 patients; 95% CI: 0.9-24.3) (p=0.34). Median PFS for PD-L1 high and PD-L1 low/negative patients was 5.3 (95% CI: 1.4-17.8) and 1.7 (95% CI: 1.4-8.3) months, respectively, while median OS was 20.2 (95% CI: 4.9-not estimable) and 10.2 (95% CI: 3.8-21.0) months, respectively. Using a 1% cut-off for PD-L1 positive (PD-L1+) and negative (PD-L1-) definition, ORR was 14% (3 patients; 95% CI: 2.9-34.9) and 10% (2 patients; 95% CI: 1.2-30.4), respectively (p= 1.00). In PD-L1+, the median PFS was 5.3 months (95% CI: 1.4-12.0) as compared to 1.6 months in PD-L1- patients (95% CI: 1.4-6.8). The median OS was 20.2 months (95% CI: 6.1- not estimable) and 7.5 months (95% CI: 3.8-21.0) in PD-L1+ and PD-L1-, respectively.

3.1.3 Durvalumab

No results from clinical trials evaluating the anti PD-L1 mAb durvalumab in pre-treated asMM were found. This agent has been studied in 2 single-arm phase 2 trials combined with
chemotherapy in treatment-naïve, unresectable malignant pleural mesothelioma (MPM) patients. A phase 3 randomized trial comparing cisplatin plus pemetrexed plus durvalumab versus cisplatin plus pemetrexed is initiating enrolment [NCT 04334759].

### 3.1.4 Nivolumab

The fully human anti-PD-1 Ig G4 mAb nivolumab has been studied in MM alone or in combination with anti-CTLA-4 mAbs. Nivolumab was administered at 3 mg/kg q2w in a single-arm, single-centre, phase II trial in advanced stage MPM patients progressing to at least one prior chemotherapy, with ECOG-PS 0-1. Tumour assessment was performed by RECIST modified for MM (mRECIST) and immune RECIST (iRECIST). The DCR at 12 weeks was the primary end-point. The study enrolled 38 patients, 34 received nivolumab. Median age was 67 years (range 50-81), 82% (n:28) were male, 47% (n:16) had ECOG-PS 1, 82% (n:28) had epithelioid histology, and most had stage I to III disease (n:24, 71%). All but one patient received second-line nivolumab. The median number of administered doses was 7, the median DoT was 2.8 months. The 12 weeks DCR was 47% (95% CI: 30-65), with 8 partial responses (PR) (24%; 95% CI: 11-42) and another patient PR after 18 weeks, leading to 26% ORR. Three pseudo-progressions were observed. At a median follow-up of 27.5 months (95% CI: 19.3-not reached), median duration of response (DoR) was 7.0 months, while median PFS and OS were 2.6 (95% CI: 2.23-5.49) and 11.8 (95% CI: 9.7-15.7) months, respectively. Nine cases (27%) were PD-L1+ (cut-off 1% by 28-8 antibody), mostly epithelioid. Among them, clinical benefit (PR or long-term stable disease- SD) was observed in 5 (55%), with 4 experiencing PR. Overall, 8 out of 23 (34.8%) evaluable PD-L1- patients had clinical benefit.

The single-arm phase 2 trial MERIT had a similar design differing for the nivolumab dose (240 mg q2w) and the number of previous chemotherapy lines (no more than 2, including platinum-pemetrexed combination). The primary end-point ORR was centrally assessed by mRECIST. Thirty-four patients were enrolled, the median age was 68 years, 79% (n:27) had epithelioid histology. Median DoT was 6.8 months (median number of doses: 12.5). At a median follow-up of 12.8 months, ORR was 29% (95% CI: 16.8-46.2) and DCR was 68% (95% CI: 50.8-80.9). Median OS and PFS were 17.3 (95% CI: 11.5-not reached) and 6.1 (95% CI: 2.9-9.9) months, respectively. 59% of patients (n:20) was PD-L1+ (cut-off 1% by 28-8 antibody), 12% (n:4) PD-L1-, in 6% (n:2) not evaluable. ORR was higher in PD-L1+ patients as compared to PD-L1- (40% vs 8%, respectively), with similar trends using higher cut-offs (5% and 10%). At the same time, PD-L1+
patients had longer OS (HR 0.542; 95% CI: 0.208-1.415, p=0.2021) and PFS (HR 0.725; 95% CI: 0.316-1.668, p=0.4490) as compared to PD-L1.

Single agent nivolumab was also investigated in a randomized phase II, non-comparative, multicentre trial (MAPS-2).11 This study enrolled patients with MPM, already treated with one or two lines of chemotherapy. Patients were randomized 1:1 to nivolumab or nivolumab plus ipilimumab. Nivolumab was administered at 3 mg/Kg dose q2w. Disease assessment was performed every 12 weeks (mRECIST criteria), with central revision. PD-L1 expression was assessed using 28-8 pharmDx (n:99) and SP-263 clones (n:104), with high expression defined as ≥25% or ≥50% tumour cells expressing PD-L1. An exploratory cut-off threshold was defined on results from a post-hoc analysis. The primary end-point was DCR at 12 weeks, secondary objectives included OS and PFS. Among the 132 recruited patients, 68 were randomized to single agent nivolumab and 63 received the treatment. The median age was 72.3 years, most of the patients were male (75%), had stage III or IV disease (89%), while only 30% had ECOG-PS 0. Fifty-two patients (83%) had epithelioid histology, 44 (70%) had received one previous line. After a median follow-up of 20.1 months, the 12 weeks DCR was 44% (95% CI: 31-58), while the ORR was 19% (95% CI: 8-29). In the intention-to-treat population, the response rate (RR) was 17.5% (95% CI: 8-1-26.8), while the DCR at 12 weeks was 40% (95% CI: 28-52). The median DoR was 7.4 months (95% CI: 4.1-11.9), while median PFS and OS were 4.0 (95% CI: 2.8-5.7) and 11.9 (95% CI: 6.7-17.7) months, respectively. The subgroup analysis of ORR and DCR by PD-L1 expression were not reported separately by treatment. Overall, the ORR was significantly higher in PD-L1+ patients (using 1% cut-off with both clones) in both arms, while the 12 weeks DCR was not. Using a 25% cut-off for high expressors, both RR and DCR were significantly higher in patients with high PD-L1 expression as assessed by both clones.

Domoulin et al. reported real-world data about 59 patients affected by MPM treated with nivolumab 3 mg/Kg q2w.12 All patients were pre-treated with at least one prior platinum-antifolate regimen (54 treated in second-line). Median age was 72 years (range 50-83), 90% of patients were male, 95% with ECOG-PS 0-1. Forty-one patients had epithelioid histology. Median PFS and OS were 2.64 and 6.36 months, respectively, and ORR was 12% by mRECIST.

Another series reported 27 patients with asMM treated with nivolumab 3mg/Kg q2w. The median age of 25 evaluable patients was 67 years (range 38-89), 72% were male, 56% had ECOG-PS ≥2, 76% had epithelioid histology.13 Median PFS was 5 months, the ORR was 24% by RECIST.
1.1 with a DCR of 60% in the whole group. Patients with PD-L1 ≥1% and <1% had a DCR of 63% and 55%, respectively.

Early results of a retrospective single-centre Japanese series including 79 patients (78.7% males, n:63) with MPM and treated with nivolumab as second- (63.2%), third- (19%) or ≥fourth-line (17.8%) were presented.14 21.5% (n=17) had an ECOG-PS ≥2, 81% (n=64) had epithelioid histology. Among 71 patients considered for efficacy, the ORR (by mRECIST) and DCR were 26.8% and 66.2%, respectively. ORR were 22.8%, 55.6%, and 20% for epithelioid, sarcomatoid, and biphasic MPM, respectively. At a median follow-up of 13.3 months (range 4.2-18.9), median PFS and OS were 4.1 and 14.3 months, respectively. At multivariate analysis, PS ≥2 was an independent negative factor for both PFS (HR 2.6; 95% CI: 1.46-4.62) and OS (HR 2.33; 95% CI: 1.30-4.15).

A randomized, double-blind, placebo-controlled clinical trial comparing nivolumab with placebo in previously treated MM is currently ongoing (CONFIRM Study, NCT 03063450).

### 3.1.5 Pembrolizumab

Pembrolizumab is a humanised Ig G4 mAb directed against PD-1. The phase IB KEYNOTE-028 study was a multicentre, non-randomised, open-label, multicohort trial of pembrolizumab in patients with advanced solid tumours with PD-L1 expression (≥1%, tested with 22C3 clone).15 Among 38 MPM patients, 25 received pembrolizumab 10 mg/Kg q2w for a maximum of 24 months. The primary end-points were safety, tolerability and ORR (by RECIST based on investigator review); PFS, OS and DoR were secondary end-points. Eighteen (72%) patients had epithelioid MPM. At a median follow-up of 18.7 months, ORR was 20% (95% CI: 6.8-40.7) and the clinical benefit rate (defined as complete response plus PR plus SD for 6 months or more) was 40% (95% CI: 21.1-61.3). The DCR was 72%. Of note, two additional patients had a reduction in tumour size of more than 30% but were not included in the confirmed ORR as they did not have a subsequent confirmatory imaging. Median PFS and OS were 5.4 (95% CI: 3.4-7.5) and 18 (95% CI: 9.4-not reached) months, respectively.

A registry study enrolled 93 patients with unresectable MPM, both untreated and previously treated with chemotherapy.16 Data collection was retrospective, with PD-L1 evaluation by SP263 clone or by E1L3N clone. Pembrolizumab was administered at different doses (200 mg q3w or q2w, 10 mg/Kg q2w, 2 mg/Kg q2w or q3w). Sixty-six patients (71%) had ECOG-PS 0-1, the median age was 68 years (range 25-94), most patients were male (91%, n:85), 67 (73%) had epithelioid
histology. Four patients received pembrolizumab as first-line, 48 as second-line (52%), and 41 (48%) as third-line or subsequent. At a median follow-up of 9 months, the ORR was 18% and the DCR was 48% in the whole cohort. Median PFS and OS were 3.1 (95% CI: 2.6-6.4) and 7.2 (95% CI: 4.9-10.0) months, respectively. PD-L1 expression was associated with ORR and DCR at the univariate analysis but not at the multivariate analysis.

Desai et al. conducted a two-part, phase II, single-centre, non-randomised trial enrolling patients with MM. The part A enrolled 35 unselected patients to determine the ORR to pembrolizumab (200 mg q3w) and to find the optimal PD-L1 cut-off for positivity (22C3 clone). The part B was initiated when 7 responses were reported in part A, and intended to use a biomarker enrichment strategy for PD-L1. However, as no PD-L1 cut-off was established in part A, part B enrolled 30 patients irrespective of PD-L1 level. All enrolled patients previously received at least one previous line of therapy, including platinum and pemetrexed, but no more than 2 systemic regimens. eTh median age was 68 years (range 26-85), 77% were male, and 53% had ECOG-PS 0. 77% had epithelioid histology, 88% had pleural mesothelioma while 12% had peritoneal, and 61% had already received one previous systemic treatment. Disease assessment was performed by mRECIST. ORR was 22% and DCR was 63%. Median PFS and OS were 4.1 and 11.5 months, respectively. PD-L1 expression ≥50% was associated with higher RR and longer median PFS.

The cohort study by Cengel et al enrolled 82 patients and evaluated ORR (by mRECIST), PFS and OS. Median age was 72 years, and 59 were male. Sixty-three patients had epithelioid histology, 42 treated in second-line. PD-L1 expression was not determined in 45 patients, <1% in 16, and ≥1% in 21. Median OS of the entire population was 8.5 months, median PFS 4.2 months, ORR 25%, and DCR 71%.

In 2019, the results of a phase III, open-label, randomized PROMISE-meso trial have been presented. This trial randomized 1:1 MPM patients, who progressed to platinum-based chemotherapy, to receive either pembrolizumab 200 mg q3w or chemotherapy based on investigator choice (gemcitabine or vinorelbine). Histological subtype (epithelioid vs non-epithelioid) was the only stratification factor, while PD-L1 expression was exploratory. The primary end-point was PFS (assessed by blinded independent central review), and secondary end-points were ORR (by RECIST 1.1), time to treatment failure, OS, investigator-assessed PFS and adverse events. The study enrolled 144 patients (73 treated with pembrolizumab, 50.7%), 90% with epithelioid histology, 80% males. After a median follow-up of 11.8 months, pembrolizumab arm showed a median PFS of 2.5 months as compared to 3.4 months of the
control (HR 1.06, 95% CI: 0.73-1.53, p=0.76 stratified by histological subtype). Pembrolizumab led to a superior ORR (22% vs 6%, p=0.004), while the median DoR was higher with chemotherapy (11.2 months vs 4.6 months). Median OS was 10.7 and 11.7 months in the experimental and control arm, respectively (HR 1.04, 95% CI: 0.66-1.67, p=0.85), without differences even after adjusting for cross-over. The DCR in the pembrolizumab group was 45%, with 16 patients achieving PR and 17 SD. No differences were observed neither in median PFS nor in OS according to PD-L1 expression (TPS <1% vs ≥1%).

A retrospective single-centre cohort study of pembrolizumab in MPM included 13 non-papillary peritoneal tumours, all pre-treated with chemotherapy. Median age of enrolled patients was 65.6 years, 62% had known asbestos exposure. Histology was epithelioid in 70% of cases. ORR was 18%, while DCR was 81%. Median PFS and OS were 5.7 and 20.9 months, respectively. No differences in PFS were observed comparing epithelioid histology vs others, or by PD-L1 status (positive vs negative, median PFS 5.1 vs 5.7 months respectively, p=0.73).

Another retrospective real-world study included 98 patients with MM (95 pleural, 3 peritoneal) treated with pembrolizumab. Median age was 70 years (range 46-91), most patients were male (92%) and with ECOG-PS of 0-1 (78%), 76% had epithelioid histology. Four patients received pembrolizumab as first-line because unfit for chemotherapy, while the others were chemotherapy pre-treated (64% one previous line). Pembrolizumab was administered at 200 mg q3w (73%) or at 2 mg/Kg q3w (27%), the median number of cycles was 6 (range 1-35). PD-L1 was assessed with. Using a 1% cut-off, PD-L1 expression (E1L3N clone) resulted negative in 46%, positive in 32%, while for remaining data was missing. ORR was 18% (95% CI: 12-28%) as per investigator-assessed mRECIST, and DCR 56% (95% CI: 47-66). The median PFS and OS were 4.8 (95% CI: 3.6-6.2) and 9.5 (6.6-13.7) months, respectively. PD-L1 expression and BRCA1 associated protein 1 (BAP1) loss were not associated with objective response, although ORR was numerically higher in PD-L1+ patients (23% vs 11%) and those with BAP1 loss (20% vs 13%).

Finally, 4 patients affected by asMM were enrolled into the Keynote-158 trial, a phase 2 study assessing the efficacy of pembrolizumab in patients with non-colorectal high microsatellite instability/mismatch repair deficient tumours. Among 233 enrolled patients, ORR was 34.3% (95% CI: 28.3-40.8) and the median PFS and OS were 4.1 (95% CI: 2.4-4.9) and 23.5 (95% CI: 13.5-not reached) months, respectively. However, data about patients with asMM are not available.

3.2 Meta-analysis
We selected 10 studies including 497 patients, most with pleural MM.\textsuperscript{6,9–12,14,15,17,19,20} Table 1 summarizes the main characteristics of the selected trials. Four studies were excluded due to the inclusion of treatment naïve patients,\textsuperscript{13,16,18,21} while one study because no data on asMM patients were available.\textsuperscript{22} The analysis of patients from the phase III PROMISE-meso trial was restricted to those assigned to pembrolizumab (n:73).\textsuperscript{19} Data on responses were available for 487 patients, irrespective of PD-L1 levels. A total of 434 patients (89.1%) received anti-PD-1 inhibitors (nivolumab [N] or pembrolizumab [P]), while 53 (10.9%) were treated with avelumab (A) [Table 1]. In aggregate, ORR was 20.1% (95% CI: 16.8-23.9%) with no significant differences between drugs (N:21.5%, P:21.4%, A:9.4%; p=0.121. \( I^2=26.18\%, p=0.2027 \)) [Figure 2]. DCR was 54.6% (95% CI: 50.2-59.0%) without significant differences between agents (N:51.7%, P:57.8%, A:58.5%; p=0.385. \( I^2=68.14\%, p=0.0009 \)) [Figure 2]. In unselected patients, the median PFS ranged from 2.5 to 6.1 months, while the median OS from 6.36 to 20.9 months. Tumour response according to PD-L1 expression were reported in 6 out of 10 studies, with PD-L1 positivity defined using heterogeneous cut-offs depending of each different trial (ranging from 1% to 50%).\textsuperscript{6,9–11,15,17} This subgroup included 125 and 131 patients, depending on the clone adopted in the study by Scherpereel et al. (n: 125 for 28-8, n: 131 for SP-263) [Table 2].\textsuperscript{11} ORR was 34.4% (95% CI: 26.7-43.1%). \( I^2=28.52\%, p=0.2210 \) and 32.1% (95% CI: 24.7-40.5%). \( I^2=22.23\%, p=0.2667 \), respectively, although it ranged from 19% to 56% in different studies [Figure 3]. No publication biases were found at a significance level < 0.05 [Figure 4, Figure 5].

4. Discussion

The present study performed a systematic review and meta-analysis to evaluate the activity of anti-PD-1/PD-L1 in pre-treated asMM in terms of ORR and DCR. Notably, higher efficacy is observed in tumours whose aetiology is associated to carcinogens exposure.\textsuperscript{23–25} Therefore, the assessment of the efficacy of ICIs in asMM finds a rationale as most of the cases are related to asbestos exposure. Unfortunately, most of the studies about ICIs in asMM do not report this information. At the same time, MM is partially resistant to cytotoxic chemotherapy and second-line treatments have never formally demonstrated to increase survival as compared to best supportive care. Indeed, international guidelines suggest the treatment with vinorelbine or gemcitabine in pre-treated patients, reporting ORR between 7% and 16%.\textsuperscript{26–30} The present meta-analysis indicates that ICIs provide an ORR of 20.1% and a DCR of 54.6%, without significant differences between drugs. Overall, the heterogeneity between the studies was low
when evaluating the ORR, both in the entire population and in patients whose tumours expressed PD-L1, while the heterogeneity was significant for the evaluation of the DCR. We did not found significant evidence of publication bias. However, the results of the phase 3 PROMISE-meso trial showed that, despite the higher ORR with pembrolizumab, no survival differences were observed as compared to single agent chemotherapy in pre-treated advanced stage MPM.\textsuperscript{19} Notably, this trial was designed with PFS as primary end-point. OS events were 71 at the time of the analysis, leading to a 16% statistical power for a HR of 0.8, meaning that the study was not powered to allow meaningful conclusion about OS. Indeed, the interpretation of these results is challenging. Since most of the studies included in our meta-analysis lack of a comparison arm, we were not capable to compare ICIs with single-agent chemotherapy. However, to our knowledge, ORR has never been demonstrated to be a surrogate marker of survival in MM. Moreover, the selected trials have used different criteria for response evaluation such as mRECIST and iRECIST, and some of the considered cases did not have independent assessment. For this latter reason, as most studies were single-arm trials, observer bias could not be ruled out. The present meta-analysis suggests that PD-L1+ tumours might better respond to single-agent immunotherapy. However, trials are highly heterogeneous when accounting for PD-L1 evaluation because different IHC clones and cut-offs were used, so that these data should be taken with caution. Moreover, a recent publication reported that the antigenic potential of mesothelioma could be better predicted by other factors, including chromosomal rearrangements (chromoplexy and chromothripsis).\textsuperscript{31} Such interesting data deserve more studies in the context of ICIs therapy for MM. Adoptive immunotherapy as well as vaccines, alone or in combination with ICIs, are another active field of investigation. Preliminary results of a phase I study of intrapleural injection of mesothelin-targeted chimeric antigen receptor T-cell (CAR-T) therapy, with or without anti PD-1 agents, showed 63% RR in 18 asMM patients, 37% of which already treated with 3 or more lines of therapy.\textsuperscript{32} The treatment landscape of asMM is therefore expected to change, and immunotherapy may have a pivotal role both in treatment-naïve and pre-treated patients. The recent results of the Checkmate 743 trial, showing that nivolumab plus ipilimumab led to significantly longer OS as compared to platinum plus pemetrexed in untreated unresectable MPM, are starting this paradigm shift.\textsuperscript{33} Non-epithelioid tumors seem to derive the most benefit. Unfortunately, due to the lack of specific data, we could not evaluate the activity of single-agent ICIs in different histologies. As results of other ongoing
studies are eagerly awaited, our meta-analysis suggests that anti-PD-(L)1 agents might be useful in some chemotherapy pre-treated patients, even if reliable predictive factors are still lacking.
References


**Figure legends**

Figure 1. PRISMA flowchart of selected trials

Figure 2. Objective response rate of trials selected for the meta-analysis and aggregate data

*Abbreviations.* ORR: objective response rate.

Figure 3. Objective response rate of trials reporting activity according to PD-L1 expression and aggregate data

*Abbreviations.* ORR: objective response rate.

Figure 4. Funnel plot for objective response rate

Figure 5. Funnel plot for disease control rate
A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma

Abstract
Introduction
Advanced stage malignant mesothelioma (asMM) patients have poor prognosis. Several trials investigated the role of programmed cell death protein-1 (PD-1) and its ligand 1 (PD-L1) immune checkpoint inhibitors (ICIs) in pre-treated asMM.

Methods
A systematic review of the literature of clinical trials testing single-agent anti PD-1/PD-L1 ICIs in pre-treated asMM was performed. Objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS) and overall survival (OS) data were extracted. The predictive role of PD-L1 was assessed.

Results
We selected 13 studies including 888 patients. ORR and DCR were 18.1% (95% confidence interval [CI] 13.9-22.8%) and 55.4% (95% CI: 48.1-62.5%), respectively. Median PFS and OS ranged from 2.1 to 5.9 and from 6.7 to 20.9 months, respectively. ORR according to PD-L1 was 27.0% (95% CI: 18.7-36.2%).

Conclusions
Anti-PD-(L)1 ICIs might be considered a treatment option for chemotherapy-resistant asMM, even if reliable predictive factors are still lacking.

Keywords
Mesothelioma; immune checkpoint inhibitors; nivolumab; pembrolizumab; avelumab

Abbreviations
DoR: duration of response
RR: response rate
PR: partial response
SD: stable disease
BAP1: BRCA1 associated protein 1
CAR-T: chimeric antigen receptor T-cell
1. Introduction

Malignant mesothelioma (MM) is a rare and aggressive tumour of mesothelial surfaces. Asbestos exposure is the main risk factor, even if this neoplasm can occur in non-exposed subjects and rarely can be due to germline mutations.¹ The combination of platinum and pemetrexed has been for decades the standard systemic first-line treatment, providing a small although significant survival benefit as compared to platinum alone, and better symptom control.² One randomized study the addition of bevacizumab improved progression-free and overall survival (PFS and OS) as compared to chemotherapy alone.³ Overall clinical results are still modest, claiming for novel approaches to significantly increase survival of MM patients. In the last few years, immune checkpoint inhibitors (ICIs) radically changed treatment paradigm of many solid tumours. While cytotoxic T-lymphocyte antigen-4 (CTLA-4) directed agents alone did not confer any benefit in advanced MM,⁴ their combination with a programmed cell death protein-1 (PD-1) inhibitor recently demonstrated to be superior to platinum plus pemetrexed in a phase 3 randomized trial in treatment naïve advanced pleural MM patients.⁵ However, the magnitude of benefit seems superior in non-epithelioid MM, while at best modest in epithelioid tumors.⁶ Several trials and case-series suggest that PD-1) and programmed death-ligand 1 (PD-L1) antagonists may increase survival in chemotherapy pre-treated advanced stage MM (asMM) patients too.⁷ However, such results are still debated because the only randomized trial with active control did not show survival differences between pembrolizumab and single agent chemotherapy, while another placebo-controlled study showed the superiority of nivolumab as compared to best supportive care.⁸ To this end, we performed a systematic review and meta-analysis to define the activity and efficacy of PD-1/PD-L1 monoclonal antibodies (mAbs) in chemotherapy pre-treated asMM patients.

2. Material and Methods

2.1 Trial identification criteria

We identified all clinical trials testing ICIs in pre-treated asMM as single-agent in single-arm as well as multi-arm studies. The following Mesh terms were used: “mesothelioma”, “malignant mesothelioma”, “atezolizumab”, “avelumab”, “durvalumab”, “nivolumab”, “pembrolizumab”, “immunotherapy”, “PD-1”, “PD-L1”. Search was made on Pubmed/Medline and Cochrane library on January 20th, 2022. Papers published in peer-reviewed journals and in English language were selected. We also searched proceedings of major International meetings such as American Society of Clinical Oncology- ASCO annual meetings, European Society of Medical Oncology- ESMO annual
meetings, International Association for the Study of Lung Cancer- IASLC World Conferences on Lung Cancer, European Lung Cancer Congress- ELCC from 2014 onwards for relevant abstracts. When more than one report of the same study was available, the most recent data (with longer follow-up and/or higher number of patients) were considered (Figure 1).

2.2 Aims of the meta-analysis
- (i) To evaluate the activity of single-agent PD-1/PD-L1 directed ICIs in chemotherapy pre-treated asMM in terms of objective response rate (ORR) and disease control rate (DCR);
- (ii) To evaluate the efficacy of single-agent PD-1/PD-L1 directed ICIs in chemotherapy pre-treated asMM in terms of PFS and OS;
- (iii) To explore the potential role of PD-L1 expression as a predictive marker of activity. For this aim, the ORR and DCR analyses were repeated in the subgroup of patients included, within each trial, in the highest category of PD-L1 expression (even if with heterogeneous methods and cut-offs).

2.3 Data extraction for the meta-analysis
The following data were extracted from each study: (a) first author, phase of the study, and year of publication; (b) type of ICIs agent and number of patients assigned to the experimental treatment; (c) percentage of patients treated in second-line; (d) site of MM (pleural vs peritoneal vs others) and histology; (e) median follow-up and range; (f) ORR (number of patients obtaining objective response) in the whole study population and in the “PD-L1 high” subpopulation; in the randomized trial, ORR was collected for both treatment arms in order to calculate odds ratio; (g) DCR (number of patients obtaining objective response or disease stabilization) in the study population and in the “PD-L1 high” subpopulation; in the randomized trial, DCR was collected for both treatment arms in order to calculate odds ratio; (g) median PFS and median OS; in the randomized trial, hazard ratio (HR) and 95% confidence interval (CI) of experimental treatment compared to control arm, in the intention to treat population, were collected. Outcome results by histologic subtypes were also collected to provide a descriptive analysis.

2.4 Data analysis
Meta-analysis on response/disease control rates was performed with MedCalc Statistical Software version 20.015 (MedCalc Software Ltd, Ostend, Belgium; https://www.medcalc.org; 2021).
Freeman-Tukey transformation (arcsine square root transformation) was used to calculate the weighted summary proportion under the fixed and random effects model. Heterogeneity was measured by Cochran’s Q, calculated as the weighted sum of squared differences between individual study proportion and the pooled proportion across studies. The I² statistic was used to describe the percentage of variation across studies that is due to heterogeneity. The likelihood of publication bias was assessed by both Egger’s and Begg’s tests and by visual inspection of funnel plots.

3. Results

3.1 Systematic review of the literature

3.1.1 Atezolizumab

No results from clinical trials evaluating the anti PD-L1 mAb atezolizumab in pre-treated aMM were found. A randomized phase 3 trial comparing carboplatin plus pemetrexed plus bevacizumab with or without atezolizumab is ongoing in treatment-naive aMM [NCT03762018]

3.1.2 Avelumab

Avelumab has been evaluated in aMM within the phase Ib JAVELIN trial.9 Fifty-three patients with unresectable pre-treated MM received avelumab 10 mg/Kg every two weeks (q2w). Median age was 67 years (range 32-84), and median number of previous lines was 2 (range 1-8). Thirty-two patients (60%) were male, and 39 (74%) had an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 1. Most patients had epithelioid histology (n:43, 81%). PD-L1 expression, evaluated with Dako PD-L1 immunohistochemistry (IHC) 73-10 pharmDx, was ≥1% in 21 patients (40%), negative in 22 patients (42%), not evaluable in 10 (19%). High PD-L1 expression (≥5% of positive tumour cells) was reported in 16 patients (30%), while 27 (51%) had a low/negative expression. The median duration of treatment (DoT) was 2.8 months (range 0.9-28.1), with a median of 6 delivered doses (range 2-59). At a median follow-up of 24.8 months (range 16.8-27.8), the ORR (by Response Evaluation Criteria in Solid Tumours- RECIST 1.1) was 9% (95% CI: 3.1-20.7) and the DCR was 58% (n:31). Median PFS and OS were 4.1 (95% CI: 1.4-6.2) and 10.7 (95% CI: 6.4-20.2) months, respectively. ORR was higher in PD-L1 high (19%, 3 out of 16 patients; 95% CI: 4.0-45.6) than in low/negative patients (7%, 2 out of 27 patients; 95% CI: 0.9-24.3) (p=0.34). Median PFS for PD-L1 high and PD-L1 low/negative patients was 5.3 (95% CI:
1.4-17.8) and 1.7 (95% CI: 1.4-8.3) months, respectively, while median OS was 20.2 (95% CI: 4.9-not estimable) and 10.2 (95% CI: 3.8-21.0) months, respectively. Using a 1% cut-off for PD-L1 positive (PD-L1+) and negative (PD-L1-) definition, ORR was 14% (3 patients; 95% CI: 2.9-34.9) and 10% (2 patients; 95% CI: 1.2-30.4), respectively (p= 1.00). In PD-L1+, the median PFS was 5.3 months (95% CI: 1.4-12.0) as compared to 1.6 months in PD-L1- patients (95% CI: 1.4-6.8). The median OS was 20.2 months (95% CI: 6.1- not estimable) and 7.5 months (95% CI: 3.8-21.0) in PD-L1+ and PD-L1-, respectively.

3.1.3 Durvalumab

No results from clinical trials evaluating the anti PD-L1 mAb durvalumab in pre-treated asMM were found. This agent has been studied in 2 single-arm phase 2 trials combined with chemotherapy in treatment-naïve, unresectable malignant pleural mesothelioma (MPM) patients. A phase 3 randomized trial comparing cisplatin plus pemetrexed plus durvalumab versus cisplatin plus pemetrexed is ongoing [NCT04334759].

3.1.4 Nivolumab

Nivolumab has been studied in MM alone or in combination with anti-CTLA-4 mAbs. Nivolumab was administered at 3 mg/kg q2w in a single-arm, single-centre, phase II trial in advanced stage MPM patients progressing to at least one prior chemotherapy, with ECOG-PS 0-1. Tumour assessment was performed by RECIST modified for MM (mRECIST) and immune RECIST (iRECIST). The DCR at 12 weeks was the primary end-point. The study enrolled 38 patients, 34 received nivolumab. Median age was 67 years (range 50-81), 82% (n:28) were male, 47% (n:16) had ECOG-PS 1, 82% (n:28) had epithelioid histology, and most had stage I to III disease (n:24, 71%). All but one patient received second-line nivolumab. The median number of administered doses was 7, the median DoT was 2.8 months. The 12 weeks DCR was 47% (95% CI: 30-65), with 8 partial responses (PR) (24%; 95% CI: 11-42) and another patient PR after 18 weeks, leading to 26% ORR. Three pseudo-progressions were observed. At a median follow-up of 27.5 months (95% CI: 19.3-not reached), median duration of response (DoR) was 7.0 months, while median PFS and OS were 2.6 (95% CI: 2.23-5.49) and 11.8 (95% CI: 9.7-15.7) months, respectively. Nine cases (27%) were PD-L1+ (cut-off 1% by 28-8 antibody), mostly epithelioid. Among them, clinical benefit (PR or long-term stable disease- SD) was observed in 5 (55%), with 4 experiencing PR. Overall, 8 out of 23 (34.8%) evaluable PD-L1- patients had clinical benefit.
The single-arm phase 2 trial MERIT had a similar design differing for the nivolumab dose (240 mg q2w) and the number of previous chemotherapy lines (no more than 2, including platinum-pemetrexed combination).\textsuperscript{13,14} The primary end-point ORR was centrally assessed by mRECIST. Thirty-four patients were enrolled, the median age was 68 years, 79% (n:27) had epithelioid histology. Median DoT was 6.8 months (median number of doses: 12.5). ORR was 29% (95% CI: 16.8-46.2) and DCR was 68% (95% CI: 50.8-80.9). At a median follow-up of 17.3 months, median OS and PFS were 17.3 (95% CI: 11.5-26.6) and 5.9 (95% CI: not reported) months, respectively. 59% of patients (n:20) was PD-L1+ (cut-off 1% by 28-8 antibody), 35% (n:12) PD-L1-, in 6% (n:2) not evaluable. ORR was higher in PD-L1+ patients as compared to PD-L1- (40% vs 8%, respectively). At the same time, PD-L1+ patients did not have longer OS (HR 0.98; 95% CI: 0.43-2.23, p=0.969) and PFS (HR 0.82; 95% CI: 0.37-1.82, p=0.629) as compared to PD-L1-.

Single agent nivolumab was also investigated in a randomized phase II, non-comparative, multicentre trial (MAPS-2).\textsuperscript{15} This study enrolled patients with MPM, already treated with one or two lines of chemotherapy. Patients were randomized 1:1 to nivolumab or nivolumab plus ipilimumab. Nivolumab was administered at 3 mg/Kg dose q2w. PD-L1 expression was assessed using 28-8 pharmDx (n:99) and SP-263 clones (n:104), with high expression defined as ≥25% or ≥50% tumour cells expressing PD-L1. The primary end-point was DCR at 12 weeks, OS and PFS were secondary objectives Overall, 68 out of 132 patients were randomized to single agent nivolumab and 63 received the treatment. The median age was 72.3 years, most of the patients were male (75%), had stage III or IV disease (89%) and 30% had ECOG-PS 0. Fifty-two patients (83%) had epithelioid histology, 44 (70%) had received one previous line. After a median follow-up of 20.1 months, the 12 weeks DCR was 44% (95% CI: 31-58), while the ORR was 19% (95% CI: 8-29). In the intention-to-treat population, the response rate (RR) was 17.5% (95% CI: 8.1-26.8), while the DCR at 12 weeks was 40% (95% CI: 28-52). The median DoR was 7.4 months (95% CI: 4.1-11.9), while median PFS and OS were 4.0 (95% CI: 2.8-5.7) and 11.9 (95% CI: 6.7-17.7) months, respectively. The subgroup analysis of ORR and DCR by PD-L1 expression were not reported separately by treatment. Overall, the ORR was significantly higher in PD-L1+ patients (using 1% cut-off with both clones) in both arms, while the 12 weeks DCR was not. Using a 25% cut-off for high expressors, both RR and DCR were significantly higher in patients with high PD-L1 expression as assessed by both clones.

Real-world data about 107 patients affected by MPM treated with nivolumab 3 mg/Kg q2w within the Dutch expanded access program were reported.\textsuperscript{16,17} All patients were pre-treasted
with at least one prior platinum-antifolate regimen (97 treated in second-line). Median age was 69 years (range 34-84), 87% of patients were male, 83% with ECOG-PS 0-1, 78 patients had epithelioid histology. Median PFS and OS were 2.3 (95% CI 1.6-2.9) and 6.7 (95% CI 6.2-10.0) months, respectively, and ORR and DCR by mRECIST were 10% and 37%, respectively.

Another series reported 27 patients with asMM treated with nivolumab 3mg/Kg q2w. The median age of 25 evaluable patients was 67 years (range 38-89), 72% were male, 56% had ECOG-PS >2, 76% had epithelioid histology. Median PFS was 5 months, the ORR was 24% by RECIST 1.1 with a DCR of 60% in the whole group. Patients with PD-L1 ≥1% and <1% had a DCR of 63% and 55%, respectively.

Early results of a retrospective single-centre Japanese series including 79 patients (78.7% males, n:63) with MPM treated with nivolumab as second- (63.2%), third- (19%) or ≥fourth-line (17.8%) were presented.21 21.5% (n=17) had an ECOG-PS ≥2, 81% (n:64) had epithelioid histology. Among 71 patients considered for efficacy, the ORR and DCR by mRECIST were 26.8% and 66.2%, respectively. ORR were 22.8%, 55.6%, and 20% for epithelioid, sarcomatoid, and biphasic MPM, respectively. At a median follow-up of 13.3 months (range 4.2-18.9), median PFS and OS were 4.1 and 14.3 months, respectively. At multivariate analysis, PS >2 was an independent negative factor for both PFS (HR 2.6; 95% CI: 1.46-4.62) and OS (HR 2.33; 95% CI: 1.30-4.15).

The randomized, double-blind, placebo-controlled CONFIRM trial compared nivolumab with placebo in previously treated MM with a 2:1 allocation proportion.8 Overall, 221 patients were assigned to the nivolumab arm. Their median age was 74 years (IQR 65-74), 76% (n:167) were male, 95% (n:211) had MPM, 88% (95%) had epithelioid histology. The ORR with nivolumab compared with placebo was significantly higher: 11% vs 1% (25 vs 1 partial responses, odds ratio 14.0, p=0.00086), while the DCR was 64% vs 55%. Tumors from 161 patients treated with immunotherapy were evaluable for PD-L1 expression and 60 resulted to be positive (defined as 1% threshold 1% with clone 22-C3 clone). Median OS was 10.2 months (95% CI 8.5-12.1) in the nivolumab group and 6.9 months (95% CI: 5.0-8.0;) in the placebo group (HR 0.69, 95% CI: 0.52-0.91, p=0.0090). Median PFS by investigators was 3.0 (95% CI: 2.8-4.1) and 1.8 months (1.4-2.6) months in the nivolumab and placebo group, respectively (HR 0.67, 95% CI: 0.53-0.85, p=0.0012). Seven out of 60 patients (12%) with PD-L1 positive MM achieved a partial response with nivolumab.

### 3.1.5 Pembrolizumab
The phase IB KEYNOTE-028 study was a multicentre, non-randomised, open-label, multicohort trial of pembrolizumab in patients with advanced solid tumours with PD-L1 expression (>1%, tested with 22C3 clone). Among 38 MPM patients, 25 received pembrolizumab 10 mg/Kg q2w for a maximum of 24 months. The primary end-points were safety, tolerability and ORR (by RECIST based on investigator review); PFS, OS and DoR were secondary end-points. Eighteen (72%) patients had epithelioid MPM. At a median follow-up of 18.7 months, ORR was 28% and the DCR (was 76% median PFS and OS were 5.8 (95% CI: 3.4-8.2) and 18 (95% CI: 9.4-not reached) months, respectively.

A registry study enrolled 93 patients with unresectable MPM, both untreated and previously treated with chemotherapy. Data collection was retrospective, with PD-L1 evaluation by SP263 clone or by E1L3N clone. Pembrolizumab was administered at different doses (200 mg q3w or q2w, 10 mg/Kg q2w, 2 mg/Kg q2w or q3w). Sixty-six patients (71%) had ECOG-PS 0-1, the median age was 68 years (range 25-94), most patients were male (91%, n:85), 67 (73%) had epithelioid histology. Four patients received pembrolizumab as first-line, 48 as second-line (52%), and 41 (48%) as third-line or subsequent. At a median follow-up of 9 months, the ORR was 18% and the DCR was 48% in the whole cohort. Median PFS and OS were 3.1 (95% CI: 2.6-6.4) and 7.2 (95% CI: 4.9-10.0) months, respectively. PD-L1 expression was associated with ORR and DCR at the univariate analysis but not at the multivariate analysis.

Desai et al. conducted a two-part, phase II, single-centre, non-randomised trial enrolling patients with MM. The part A enrolled 35 unselected patients to determine the ORR to pembrolizumab (200 mg q3w) and to find the optimal PD-L1 cut-off for positivity (22C3 clone). The part B was initiated when 7 responses were reported in part A, and intended to use a biomarker enrichment strategy for PD-L1. However, as no PD-L1 cut-off was established in part A, part B enrolled 30 patients irrespective of PD-L1 level. All enrolled patients previously received at least one previous line of therapy, including platinum and pemetrexed, but no more than 2 systemic regimens. Eth median age was 68 years (range 26-85), 77% were male, and 53% had ECOG-PS 0. 77% had epithelioid histology, 88% had pleural mesothelioma while 12% had peritoneal, and 61% had already received one previous systemic treatment. Disease assessment was performed by mRECIST. ORR was 22% and DCR was 63%. Median PFS and OS were 4.1 and 11.5 months, respectively. PD-L1 expression ≥50% was associated with higher RR and longer median PFS.

The cohort study by Cengel et al enrolled 74 patients receiving pembrolizumab after disease progression to chemotherapy and evaluated ORR (by mRECIST), PFS and OS. Median age was
73 years (range 52-92), and 55 (74%) were male. Three patients received immunotherapy as first-line. Fifty-eight (78%) patients had epithelioid histology. Median OS of the entire population was 7.9 months, median PFS 7.9 months, ORR 26%.

The PROMISE-meso was a phase III, open-label, trial that randomized 1:1 MPM patients, who progressed to platinum-based chemotherapy, to receive either pembrolizumab 200 mg q3w or chemotherapy based on investigator choice (gemcitabine or vinorelbine). Histological subtype (epithelioid vs non-epithelioid) was the only stratification factor, while PD-L1 expression was exploratory. The primary end-point was PFS (assessed by blinded independent central review), and secondary end-points were ORR (by RECIST 1.1), time to treatment failure, OS, investigator-assessed PFS and adverse events. PD-L1 immunohistochemistry was assessed by using clone SP263. The study enrolled 144 patients (73 treated with pembrolizumab, 50.7%), 89% with epithelioid histology, 82% males. After a median follow-up of 11.8 months, pembrolizumab arm showed a median PFS of 2.5 months as compared to 3.4 months of the control (HR 1.06, 95% CI: 0.73-1.53, p=0.76 stratified by histological subtype). Pembrolizumab led to a superior ORR (22% vs 6%, p=0.004), while the median DoR was higher with chemotherapy (7.2 months vs 4.6 months). Median OS was not statistically different between study arms, being 10.7 and 12.4 months in the experimental and control arm, respectively (HR 1.12, 95% CI: 0.74-1.69, p=0.59), without differences even after adjusting for cross-over. The DCR in the pembrolizumab group was 45%, with 16 patients achieving PR and 17 SD. No differences were observed neither in median PFS nor in OS according to PD-L1 expression (TPS <1% vs ≥1%).

A retrospective single-centre cohort study of pembrolizumab in MPM included 13 non-papillary peritoneal tumours, all pre-treated with chemotherapy. Median age of enrolled patients was 65.6 years, 62% had known asbestos exposure. Histology was epithelioid in 70% of cases. ORR was 18%, while DCR was 81%. Median PFS and OS were 5.7 and 20.9 months, respectively. No differences in PFS were observed comparing epithelioid histology vs others, or by PD-L1 status (positive vs negative, median PFS 5.1 vs 5.7 months respectively, p=0.73).

Another retrospective real-world study included 98 patients with MM (95 pleural, 3 peritoneal) treated with pembrolizumab. Median age was 70 years (range 46-91), most patients were male (92%) and with ECOG-PS of 0-1 (78%), 76% had epithelioid histology. Four patients received pembrolizumab as first-line because unfit for chemotherapy, while the others were chemotherapy pre-treated (64% one previous line). Pembrolizumab was administered at 200 mg q3w (73%) or at 2 mg/Kg q3w (27%), the median number of cycles was 6 (range 1-35). PD-L1
was assessed with. Using a 1% cut-off, PD-L1 expression (E1L3N clone) resulted negative in 46%, positive in 32%, while for remaining data was missing. ORR was 18% (95% CI: 12-28%) as per investigator-assessed mRECIST, and DCR 56% (95% CI: 47-66). The median PFS and OS were 4.8 (95% CI: 3.6-6.2) and 9.5 (6.6-13.7) months, respectively. PD-L1 expression and BRCA1 associated protein 1 (BAP1) loss were not associated with objective response, although ORR was numerically higher in PD-L1+ patients (23% vs 11%) and those with BAP1 loss (20% vs 13%).

Kim et al evaluated 115 patients treated with pembrolizumab, nivolumab, or nivolumab in combination with ipilimumab after disease progression to first-line platinum-based chemotherapy.28 The median age was 75 years (IQR 69-79.5), most were male (74%), and had epithelioid histology (67%). The median OS of the entire cohort was 8.7 months (95% CI: 7.7-9). Finally, 118 patients with ECOG PS 0 to 1 who had disease progression on or intolerance to standard therapy were enrolled into the MPM cohort of Keynote-158 trial, a phase 2 single-arm study assessing the efficacy of pembrolizumab.29 The median age was 68 years (IQR 61-64), 69% (n:82) had epithelioid histology, 48% (n:57) received immunotherapy as second-line; 77 out of 108 assessable tumours had positive PD-L1 expression (> 1 by 22C3 clone). ORR was 8% (95% CI: 4-15), median DoR was 14.3 months, and the median PFS and OS were 2.1 (95% CI: 2.1-3.9) and 10 (95% CI: 7.6-13.4) months, respectively. ORR in PD-L1 positive patients was 12%.

### 3.2 Meta-analysis

We selected 13 studies including 888 patients, most with pleural MM.8,9,12,14,15,17,19,20,23,25,26,29,30 Table 1 summarizes the main characteristics of the selected trials. Four studies were excluded due to the inclusion of treatment naïve patients,18,22,24,27, and one due to the inclusion of patients treated with dual ICIs combination.28 The analysis of patients from the phase III PROMISE-meso and CONFIRM trials was restricted to those assigned to immunotherapy.8,25 Data on responses were available for 888 patients, irrespective of PD-L1 levels. A total of 835 patients (94%) received anti-PD-1 inhibitors (nivolumab or pembrolizumab []), while 53 (6%) were treated with avelumab [Table 1]. In aggregate, ORR was 18.1% (95% CI: 13.9-22.8%; Cochran’s Q p=0.0011, I²=63.35%) [Figure 2]. DCR was 55.4% (95% CI: 48.1-62.5%; Cochran’s Q p<0.0001, I²=76.57%) [Figure 3]. In unselected patients, the median PFS ranged from 2.1 to 5.8 months, while the median OS from 6.7 to 20.9 months. Tumour response according to PD-L1 expression were reported in 10 out of 13 studies, with PD-L1 positivity defined using
heterogeneous cut-offs depending of each different trial (ranging from 1% to 50%).

This subgroup included 304 and 310 patients, depending on the clone adopted in the study by Scherpereel et al. (the 28-8and SP-263, respectively) [Table 2]. ORR was 28.0% (95% CI: 19.0-38.0%; Cochran’s Q p=0.0006, I²=69.03%) and 27.0% (95% CI: 18.7-36.2%; Cochran’s Q p=0.0021, I²=65.22%), respectively, although it ranged from 12% to 56% in different studies [Figure 4 forest plot of the analysis with the largest sample, accounting for the use of SP-263 clone in 15; sFigure 1 accounting for the use of 28-8 clone]. The funnel plots showed no evidence of publication bias [Figure 5, Figure 6, Figure 7, s Figure 2].

4. Discussion

We performed a systematic review and meta-analysis to evaluate the activity of anti-PD-1/PD-L1 in pre-treated asMM in terms of ORR and DCR. Notably, as higher efficacy is observed in tumours whose aetiology is associated to carcinogens exposure, ICIs evaluation in asMM finds a rational as most cases are related to asbestos exposure. Unfortunately, most of the studies about ICIs in asMM do not report this information. MM is somehow resistant to cytotoxic chemotherapy, especially non-epithelioid subtypes. The recent demonstration that the combination of the anti-CTLA-4 monoclonal antibody ipilimumab with nivolumab could significantly increase OS as compared to platinum plus pemetrexed in the first-line setting, is predicted to change the treatment landscape of this aggressive disease. However, while the superiority of ICIs combination appeared to be clear in non-epithelioid tumors, patients with epithelioid MM showed less benefit and chemotherapy may be still regarded as a treatment option, while waiting for the results of chemo-immunotherapy combination from ongoing clinical trials. Unfortunately, due to the lack of specific data, we could not evaluate the activity of ICIs in pre-treated patients according to histology. Following platinum-based chemotherapy, second-line treatments have only modest efficacy, with ORR of 8.63%, a DCR of 54.8%, and a median PFS and OS of 3.4 and 7.86 months, respectively. Only recently a formal demonstration of vinorelbine efficacy has been provided by a phase 2 trial. Moreover, another randomised phase 2 trial showed that the addition of the anti-vascular endothelial growth factor receptor 2 (VEGFR-2) monoclonal antibody ramucirumab to gemcitabine could increase OS as compared to gemcitabine and placebo in second-line setting. Our meta-analysis indicates that ICIs provide an ORR and DCR of 18.1% and 55.4%, respectively, without significant differences between agents. Overall, the heterogeneity between the studies was moderate, both in the entire
population and in patients whose tumours expressed PD-L1. No significant evidence of publication bias was found.

However, the results of the phase 3 PROMISE-meso trial showed that, despite the higher ORR with pembrolizumab, no survival differences were observed as compared to single agent chemotherapy in pre-treated asMM.\textsuperscript{25} Notably, this trial was designed with PFS as primary endpoint. OS events were 92 at the time of the analysis, leading to a 19\% statistical power for a HR of 0.8, meaning that the study was not powered to allow meaningful conclusion about OS.\textsuperscript{25} Indeed, the interpretation of these results is challenging. Since most of the studies included in our meta-analysis lack of a comparison arm, we were not able to compare ICIs with single-agent chemotherapy. However, to our knowledge, ORR has never been demonstrated to be a surrogate marker of survival in MM. Moreover, the selected trials have used different criteria for response evaluation such as mRECIST and iRECIST, and some of the considered cases did not have independent assessment. For this latter reason, as most studies were single-arm trials, observer bias could not be ruled out.

The present meta-analysis suggests that PD-L1+ tumours might better respond to single-agent immunotherapy. However, trials are highly heterogeneous when accounting for PD-L1 evaluation because different IHC clones and cut-offs were used, so that these data should be taken with caution. Indeed, available data suggest that PD-L1 expression in malignant pleural mesothelioma is prognostic, with high levels associated with poorer outcomes even after accounting for other variables such as histology and performance status.\textsuperscript{38–40} A recent publication reported that the antigenic potential of mesothelioma could be better predicted by other factors, including chromosomal rearrangements (chromoplexy and chromothripsis).\textsuperscript{41} Such interesting data deserve more studies in the context of ICIs therapy for MM. Adoptive immunotherapy as well as vaccines, alone or in combination with ICIs, are another active field of investigation. Preliminary results of a phase I study of intrapleural injection of mesothelin-targeted chimeric antigen receptor T-cell (CAR-T) therapy, with or without anti PD-1 agents, showed 63\% RR in 18 asMM patients, 37\% of which already treated with 3 or more lines of therapy.\textsuperscript{42} The treatment landscape of asMM is therefore expected to change, and immunotherapy may have a pivotal role both in treatment-naïve and pre-treated patients. Along with those from Checkmate 743, results of ongoing studies on chemo-immunotherapy combinations are expected to change the treatment landscape of untreated unresectable MPM. While waiting for these data, our meta-analysis suggests that anti-PD-(L)1
agents might be useful in some chemotherapy pre-treated patients, even if reliable predictive factors are still lacking.
**Figure legends**

Figure 1. PRISMA flowchart of selected trials

Figure 2. Objective response rate of trials selected for the meta-analysis and aggregate data

Figure 3. Disease control rate of trials selected for the meta-analysis and aggregate data

Figure 4. Objective response rate of trials reporting activity according to PD-L1 expression and aggregate data.

*Caption:* PD-L1 clone SP-263 in Scherpereel et al.

Figure 5. Funnel plot for objective response rate

Figure 6. Funnel plot for disease control rate

Figure 7. Funnel plot for objective response rate in PD-L1 positive patients (Scherpereel SP-263)

Figure 1. Objective response rate of trials reporting activity according to PD-L1 expression and aggregate data (Scherpereel 28-8)

Figure 2. Funnel plot for objective response rate in PD-L1 positive patients (Scherpereel 28-8)
REFERENCES


30. Arbour KC, Riely GJ. Systemic Therapy for Locally Advanced and Metastatic Non–Small Cell


A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma

Abstract

Introduction

Advanced stage malignant mesothelioma (asMM) patients have poor prognosis. Several trials investigated the role of programmed cell death protein-1 (PD-1) and its ligand 1 (PD-L1) immune checkpoint inhibitors (ICIs) in pre-treated asMM.

Methods

A systematic review of the literature of clinical trials testing single-agent anti PD-1/PD-L1 ICIs in pre-treated asMM was performed. Objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS) and overall survival (OS) data were extracted. The predictive role of PD-L1 was assessed.

Results

We selected 130 studies including 497,888 patients. ORR and DCR were 29.1% (95% confidence interval [CI] 13.968-22.823%) and 55.4% (95% CI: 50.2481-59.0625%), respectively. Median PFS and OS ranged from 2.15 to 4.35 months and from 6.736 to 20.9 months, respectively. ORR according to PD-L1 expression ranged from 19% to 55.5% was 27.0% (95% CI: 18.7-36.2%).

Conclusions

Anti-PD-(L)1 ICIs might be considered a treatment option for chemotherapy-resistant asMM, even if reliable predictive factors are still lacking.

Keywords

Mesothelioma; immune checkpoint inhibitors; nivolumab; pembrolizumab; avelumab

Abbreviations
MM: malignant mesothelioma
OS: overall survival
PFS: progression-free survival
ICIs: immune checkpoint inhibitors
CTLA-4: cytotoxic T-lymphocyte antigen-4
PD-1: programmed cell death protein-1
PD-L1: programmed death-ligand 1
asMM: advanced stage malignant mesothelioma
mAbs: monoclonal antibodies
ASCO: American Society of Clinical Oncology
ESMO: European Society of Medical Oncology
IASLC: International Association for the Study of Lung Cancer
ELCC: European Lung Cancer Congress
HR: hazard ratio
CI: confidence interval
ORR: objective response rate
FDA: Food and Drug Administration
EMA: European Medicines Agency
q2w: every two weeks
q3w: every three weeks
ECOG: Eastern Cooperative Oncology Group
PS: performance status
IHC: immunohistochemistry
DoT: duration of treatment
RECIST: Response Evaluation Criteria in Solid Tumours
PD-L1+: PD-L1 positive
PD-L1-: PD-L1 negative
MPM: malignant pleural mesothelioma
mRECIST: modified RECIST
iRECIST: immune RECIST
DoR: duration of response
RR: response rate
PR: partial response
SD: stable disease
BAP1: BRCA1 associated protein 1
CAR-T: chimeric antigen receptor T-cell
1. Introduction

Malignant mesothelioma (MM) is a rare and aggressive tumour of mesothelial surfaces. Asbestos exposure is the main risk factor, even if this neoplasm can occur in non-exposed subjects and rarely can be due to germline mutations. The combination of platinum and pemetrexed has been for decades the standard systemic first-line treatment, providing a small although significant survival benefit as compared to platinum alone, and better symptom control. Recently, in a randomized study the addition of bevacizumab improved progression-free and overall survival (PFS and OS) as compared to chemotherapy alone. Overall clinical results are still modest, claiming for novel approaches to significantly ameliorate the survival of MM patients. In the last few years, immune checkpoint inhibitors (ICIs) radically changed treatment paradigm of many solid tumours. While cytotoxic T-lymphocyte antigen-4 (CTLA-4) directed agents alone did not confer any benefit in advanced MM, their combination with a programmed cell death protein-1 (PD-1) inhibitor recently demonstrated to be superior to platinum plus pemetrexed in a phase 3 randomized trial in treatment naïve advanced pleural MM patients. However, the magnitude of benefit seems superior in non-epithelioid MM, while at best modest in epithelioid tumors. Several trials and case-series suggest that programmed cell death protein-1 (PD-1) and programmed death-ligand 1 (PD-L1) antagonists may increase survival in chemotherapy pre-treated advanced stage MM (asMM) patients too. However, such results are still debated because the only randomized trial with active control did not show survival differences between pembrolizumab and single agent chemotherapy, while another placebo-controlled study showed the superiority of nivolumab as compared to best supportive care. To this end, we performed a systematic review and meta-analysis to define the activity and efficacy of PD-1/PD-L1 monoclonal antibodies (mAbs) in chemotherapy pre-treated asMM patients.

2. Material and Methods

2.1 Trial identification criteria

We identified all clinical trials testing ICIs in pre-treated asMM as single-agent in single-arm as well as multi-arm studies. The following Mesh terms were used: "mesothelioma", "malignant mesothelioma", "malignant", "atezolizumab", "avelumab", "durvalumab", "nivolumab", "pembrolizumab", "immunotherapy", "PD-1", "PD-L1". Search was made on Pubmed/Medline and Cochrane library on September-January 13th, 2020. Papers published in peer-reviewed journals and in English language were selected. We also searched proceedings of major International
meetings such as American Society of Clinical Oncology- ASCO annual meetings, European Society of Medical Oncology- ESMO annual meetings, International Association for the Study of Lung Cancer- IASLC World Conferences on Lung Cancer, European Lung Cancer Congress- ELCC from 2014 onwards for relevant abstracts. When more than one report of the same study was available, the most recent data (with longer follow-up and/or higher number of patients) were considered (Figure 1).

2.2 Aims of the meta-analysis

- (i) To evaluate the activity of single-agent PD-1/PD-L1 directed ICIs in chemotherapy pre-treated asMM in terms of objective response rare (ORR) and disease control rate (DCR);
- (ii) To evaluate the efficacy of single-agent PD-1/PD-L1 directed ICIs in chemotherapy pre-treated asMM in terms of PFS and OS;
- (iii) To explore the potential role of PD-L1 expression as a predictive marker of activity. For this aim, the ORR and DCR analyses were repeated in the subgroup of patients included, within each trial, in the highest category of PD-L1 expression (even if with heterogeneous methods and cut-offs).

2.3 Data extraction for the meta-analysis

The following data were extracted from each study: (a) first author, phase of the study, and year of publication; (b) type of ICIs agent and number of patients assigned to the experimental treatment; (c) percentage of patients treated in second-line; (d) site of MM (pleural vs peritoneal vs others) and histology; (e) median follow-up and range; (f) ORR (number of patients obtaining objective response) in the whole study population and in the “PD-L1 high” subpopulation; in the randomized trial, ORR was collected for both treatment arms in order to calculate odds ratio; (g) DCR (number of patients obtaining objective response or disease stabilization) in the study population and in the “PD-L1 high” subpopulation; in the randomized trial, DCR was collected for both treatment arms in order to calculate odds ratio; (g) median PFS and median OS; in the randomized trial, hazard ratio (HR) and 95% confidence interval (CI) of experimental treatment compared to control arm, in the intention to treat population, were collected. Outcome results by histologic subtypes were also collected to provide a descriptive analysis.

2.4 Data analysis
Meta-analysis on response/disease control rates was performed with MedCalc Statistical Software version 20.015 (MedCalc Software Ltd, Ostend, Belgium; https://www.medcalc.org; 2021). Freeman-Tukey transformation (arcsine square root transformation) was used to calculate the weighted summary proportion under the fixed and random effects model. Heterogeneity was measured by Cochran’s Q, calculated as the weighted sum of squared differences between individual study proportion and the pooled proportion across studies. The I² statistic was used to describe the percentage of variation across studies that is due to heterogeneity. To obtain a quantitative measure of the degree of heterogeneity among studies included in the analysis, the Higgins I² index was computed. The likelihood of publication bias was assessed by both Egger’s and Begg’s tests and by visual inspection of funnel plots. The MedCalc® Statistical Software version 19.6 (MedCalc Software Ltd, Ostend, Belgium; https://www.medcalc.org; 2020) was used for statistical analyses.

3. Results

3.1 Systematic review of the literature

3.1.1 Atezolizumab

No results from clinical trials evaluating the anti PD-L1 mAb atezolizumab in pre-treated asMM were found. A randomized phase 3 trial comparing carboplatin plus pemetrexed plus bevacizumab with or without atezolizumab is ongoing in treatment-naive asMM (NCT03762018). However, a single-arm phase trial with atezolizumab in this population is ongoing (NCT-03786419).

3.1.2 Avelumab

Avelumab, a humanized anti-PD-L1 IgG1 mAb, has been evaluated in MM within the phase Ib JAVELIN trial. Fifty-three patients with unresectable pre-treated MM received avelumab 10 mg/Kg every two weeks (q2w). Median age was 67 years (range 32-84), and median number of previous lines was 2 (range 1-8). Thirty-two patients (60%) were male, and 39 (74%) had an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 1. Most patients had epithelioid histology (n=43, 81%). PD-L1 expression, evaluated with Dako PD-L1 immunohistochemistry (IHC) 73-10 pharmDx, was ≥1% in 21 patients (40%), negative in 22 patients (42%), not evaluable in 10 (19%). High PD-L1 expression (≥25% of positive tumour cells)
was reported in 16 patients (30%), while 27 (51%) had a low/negative expression. The median duration of treatment (DoT) was 2.8 months (range 0.9-28.1), with a median of 6 delivered doses (range 2-59). At a median follow-up of 24.8 months (range 16.8-27.8), the ORR (by Response Evaluation Criteria in Solid Tumours- RECIST 1.1) was 9% (95% CI: 3.1-20.7) and the DCR was 58% (n:31). Median PFS and OS were 4.1 (95% CI: 1.4-6.2) and 10.7 (95% CI: 6.4-20.2) months, respectively. ORR was higher in PD-L1 high (19%, 3 out of 16 patients; 95% CI: 4.0-45.6) than in low/negative patients (7%, 2 out of 27 patients; 95% CI: 0.9-24.3) (p=0.34). Median PFS for PD-L1 high and PD-L1 low/negative patients was 5.3 (95% CI: 1.4-17.8) and 1.7 (95% CI: 1.4-8.3) months, respectively, while median OS was 20.2 (95% CI: 4.9-not estimable) and 10.2 (95% CI: 3.8-21.0) months, respectively. Using a 1% cut-off for PD-L1 positive (PD-L1+) and negative (PD-L1-) definition, ORR was 14% (3 patients; 95% CI: 2.9-34.9) and 10% (2 patients; 95% CI: 1.2-30.4), respectively (p= 1.00). In PD-L1+, the median PFS was 5.3 months (95% CI: 1.4-12.0) as compared to 1.6 months in PD-L1- patients (95% CI: 1.4-6.8). The median OS was 20.2 months (95% CI: 6.1- not estimable) and 7.5 months (95% CI: 3.8-21.0) in PD-L1+ and PD-L1-, respectively.

3.1.3 Durvalumab

No results from clinical trials evaluating the anti PD-L1 mAb durvalumab in pre-treated asMM were found. This agent has been studied in 2 single-arm phase 2 trials combined with chemotherapy in treatment-naïve, unresectable malignant pleural mesothelioma (MPM) patients.10,11 A phase 3 randomized trial comparing cisplatin plus pemetrexed plus durvalumab versus cisplatin plus pemetrexed is initiating enrolment ongoing [NCT-04334759].

3.1.4 Nivolumab

The fully human anti-PD-1 Ig G4 mAb nivolumab has been studied in MM alone or in combination with anti-CTLA-4 mAbs. Nivolumab was administered at 3 mg/kg q2w in a single-arm, single-centre, phase II trial in advanced stage MPM patients progressing to at least one prior chemotherapy, with ECOG-PS 0-1.12 Tumour assessment was performed by RECIST modified for MM (mRECIST) and immune RECIST (iRECIST). The DCR at 12 weeks was the primary end-point. The study enrolled 38 patients, 34 received nivolumab. Median age was 67 years (range 50-81), 82% (n:28) were male, 47% (n:16) had ECOG-PS 1, 82% (n:28) had epithelioid histology, and most had stage I to III disease (n:24, 71%). All but one patient received second-
line nivolumab. The median number of administered doses was 7, the median DoT was 2.8 months. The 12 weeks DCR was 47% (95% CI: 30-65), with 8 partial responses (PR) (24%; 95% CI: 11-42) and another patient PR after 18 weeks, leading to 26% ORR. Three pseudo-progressions were observed. At a median follow-up of 27.5 months (95% CI: 19.3-not reached), median duration of response (DoR) was 7.0 months, while median PFS and OS were 2.6 (95% CI: 2.23-5.49) and 11.8 (95% CI: 9.7-15.7) months, respectively. Nine cases (27%) were PD-L1+ (cut-off 1% by 28-8 antibody), mostly epithelioid. Among them, clinical benefit (PR or long-term stable disease- SD) was observed in 5 (55%), with 4 experiencing PR. Overall, 8 out of 23 (34.8%) evaluable PD-L1- patients had clinical benefit.

The single-arm phase 2 trial MERIT had a similar design differing for the nivolumab dose (240 mg q2w) and the number of previous chemotherapy lines (no more than 2, including platinum-pemetrexed combination). The primary end-point ORR was centrally assessed by mRECIST. Thirty-four patients were enrolled, the median age was 68 years, 79% (n:27) had epithelioid histology. Median DoT was 6.8 months (median number of doses: 12.5). At a median follow-up of 12.8 months, ORR was 29% (95% CI: 16.8-46.2) and DCR was 68% (95% CI: 50.8-80.9). At a median follow-up of 17.3 months, median OS and PFS were 17.3 (95% CI: 11.5-not reached826) and 6.15.9 (95% CI: 2.9-9.9not reported) months, respectively. 59% of patients (n:20) was PD-L1+ (cut-off 1% by 28-8 antibody), 123.5% (n:124) PD-L1-, in 6% (n:2) not evaluable. ORR was higher in PD-L1+ patients as compared to PD-L1- (40% vs 8%, respectively), with similar trends using higher cut-offs (5% and 10%). At the same time, PD-L1+ patients did not have longer OS (HR 0.98542; 95% CI: 0.20843-12:23415, p=0.9692021) and PFS (HR 0.82225; 95% CI: 0.3716-1.82668, p=0.6729449) as compared to PD-L1-.

Single agent nivolumab was also investigated in a randomized phase II, non-comparative, multicentre trial (MAPS-2). This study enrolled patients with MPM, already treated with one or two lines of chemotherapy. Patients were randomized 1:1 to nivolumab or nivolumab plus ipilimumab. Nivolumab was administered at 3 mg/Kg dose q2w. Disease assessment was performed every 12 weeks (mRECIST criteria), with central revision. PD-L1 expression was assessed using 28-8 pharmDx (n:99) and SP-263 clones (n:104), with high expression defined as ≥25% or ≥50% tumour cells expressing PD-L1. An exploratory cut-off threshold was defined on results from a post-hoc analysis. The primary end-point was DCR at 12 weeks, secondary objectives included OS and PFS were secondary objectives. Among the 132 recruited patients, Overall, 68 out of 132 patients were randomized to single agent nivolumab and 63 received the
treatment. The median age was 72.3 years, most of the patients were male (75%), had stage III or IV disease (89%), and while only 30% had ECOG-PS 0. Fifty-two patients (83%) had epithelioid histology, 44 (70%) had received one previous line. After a median follow-up of 20.1 months, the 12 weeks DCR was 44% (95% CI: 31-58), while the ORR was 19% (95% CI: 8-29). In the intention-to-treat population, the response rate (RR) was 17.5% (95% CI: 8-1-26.8), while the DCR at 12 weeks was 40% (95% CI: 28-52). The median DoR was 7.4 months (95% CI: 4.1-11.9), while median PFS and OS were 4.0 (95% CI: 2.8-5.7) and 11.9 (95% CI: 6.7-17.7) months, respectively. The subgroup analysis of ORR and DCR by PD-L1 expression were not reported separately by treatment. Overall, the ORR was significantly higher in PD-L1+ patients (using 1% cut-off with both clones) in both arms, while the 12 weeks DCR was not. Using a 25% cut-off for high expressors, both RR and DCR were significantly higher in patients with high PD-L1 expression as assessed by both clones.

Domoulin et al. reported Real-world data about 59-107 patients affected by MPM treated with nivolumab 3 mg/Kg q2w within the Dutch expanded access program were reported16,17. All patients were pre-treated with at least one prior platinum-antifolate regimen (54-97 treated in second-line). Median age was 22-69 years (range 50-31-84), 90.7% of patients were male, 95.8% with ECOG-PS 0-1. Forty-one patients had epithelioid histology. Median PFS and OS were 2.3 (95% CI 1.6-2.9) (64) and 6.72 (95% CI 6.2-10.0) months, respectively, and ORR and DCR by mRECIST were 10.2% and 37%, respectively by mRECIST.

Another series reported 27 patients with asMM treated with nivolumab 3mg/Kg q2w. The median age of 25 evaluable patients was 67 years (range 38-89), 72% were male, 56% had ECOG-PS ≥2. 76% had epithelioid histology.18 Median PFS was 5 months, the ORR was 24% by RECIST 1.1 with a DCR of 60% in the whole group. Patients with PD-L1 ≥1% and <1% had a DCR of 63% and 55%, respectively.

Early results of a retrospective single-centre Japanese series including 79 patients (78.7% males, n=63) with MPM and treated with nivolumab as second- (63.2%), third- (19%) or fourth-line (17.8%) were presented19. 21.5% (n=17) had an ECOG-PS ≥2. 81% (n=64) had epithelioid histology. Among 71 patients considered for efficacy, the ORR by mRECIST and DCR by mRECIST were 26.8% and 66.2%, respectively. ORR were 22.8%, 55.6%, and 20% for epithelioid, sarcomatoid, and biphasic MPM, respectively. At a median follow-up of 13.3 months (range 4.2-18.9), median PFS and OS were 4.1 and 14.3 months, respectively. At multivariate analysis, PS
2 was an independent negative factor for both PFS (HR 2.6; 95% CI: 1.46-4.62) and OS (HR 2.33; 95% CI: 1.30-4.15).

The randomized, double-blind, placebo-controlled CONFIRM clinical trial comparing nivolumab with placebo in previously treated MM with a 2:1 allocation proportion is currently ongoing (CONFIRM Study, NCT 03063450). Overall, 221 patients were assigned to the nivolumab arm. Their median age was 74 years (IQR 65-74), 76% (n:167) were male, 95% (n:211) had MPM, 88% (n:211) had epithelioid histology. The ORR with nivolumab compared with placebo was significantly higher: 11% vs 1% (25 vs 1 partial responses, odds ratio 14.0, p=0.00086), while the DCR was 64% vs 55%. Tumors from 161 among patients treated with immunotherapy were evaluable for PD-L1 expression and 60 resulted to be positive (defined as 1% threshold 1% with clone 22C3 clone). Median OS was 10.2 months (95% CI 8.5-12.1) in the nivolumab group and 6.9 months (95% CI: 5.0-8.0) in the placebo group (HR 0.69, 95% CI: 0.52-0.91, p=0.0090). Median PFS by investigators was 3.0 (95% CI: 2.8-4.1) and 1.8 months (1.4-2.6) months in the nivolumab and placebo group, respectively (HR 0.67, 95% CI: 0.53-0.85, p=0.0012). Seven out of 60 patients (12%) with PD-L1 positive MM achieved a partial response with nivolumab.

3.1.5 Pembrolizumab

Pembrolizumab is a humanised Ig G4 mAb directed against PD-1. The phase IB KEYNOTE-028 study was a multicentre, non-randomised, open-label, multicohort trial of pembrolizumab in patients with advanced solid tumours with PD-L1 expression (>1%, tested with 22C3 clone). Among 38 MPM patients, 25 received pembrolizumab 10 mg/Kg q2w for a maximum of 24 months. The primary end-points were safety, tolerability and ORR (by RECIST based on investigator review); PFS, OS and DoR were secondary end-points. Eighteen (72%) patients had epithelioid MPM. At a median follow-up of 18.7 months, ORR was 28% (95% CI: 6.8-40.7) and the clinical benefit rate (defined as complete response plus PR plus SD for 6 months or more) was 40.7% (95% CI: 21.1-61.3). The DCR was 72%. Of note, two additional patients had a reduction in tumour size of more than 30% but were not included in the confirmed ORR as they did not have a subsequent confirmatory imaging. Median PFS and OS were 5.84 (95% CI: 3.4-8.22) and 18 (95% CI: 9.4-not reached) months, respectively.

A registry study enrolled 93 patients with unresectable MPM, both untreated and previously treated with chemotherapy. Data collection was retrospective, with PD-L1 evaluation by SP263
clone or by E1L3N clone. Pembrolizumab was administered at different doses (200 mg q3w or q2w, 10 mg/Kg q2w, 2 mg/Kg q2w or q3w). Sixty-six patients (71%) had ECOG-PS 0-1, the median age was 68 years (range 25-94), most patients were male (91%, n:85), 67 (73%) had epithelioid histology. Four patients received pembrolizumab as first-line, 48 as second-line (52%), and 41 (48%) as third-line or subsequent. At a median follow-up of 9 months, the ORR was 18% and the DCR was 48% in the whole cohort. Median PFS and OS were 3.1 (95% CI: 2.6-6.4) and 7.2 (95% CI: 4.9-10.0) months, respectively. PD-L1 expression was associated with ORR and DCR at the univariate analysis but not at the multivariate analysis.

Desai et al. conducted a two-part, phase II, single-centre, non-randomised trial enrolling patients with MM.23 The part A enrolled 35 unselected patients to determine the ORR to pembrolizumab (200 mg q3w) and to find the optimal PD-L1 cut-off for positivity (22C3 clone). The part B was initiated when 7 responses were reported in part A, and intended to use a biomarker enrichment strategy for PD-L1. However, as no PD-L1 cut-off was established in part A, part B enrolled 30 patients irrespective of PD-L1 level. All enrolled patients previously received at least one previous line of therapy, including platinum and pemetrexed, but no more than 2 systemic regimens. eTh median age was 68 years (range 26-85), 77% were male, and 53% had ECOG-PS 0. 77% had epithelioid histology, 88% had pleural mesothelioma while 12% had peritoneal, and 61% had already received one previous systemic treatment. Disease assessment was performed by mRECIST. ORR was 22% and DCR was 63%. Median PFS and OS were 4.1 and 11.5 months, respectively. PD-L1 expression ≥50% was associated with higher RR and longer median PFS.

The cohort study by Cengel et al enrolled 82-74 patients receiving pembrolizumab after disease progression to chemotherapy and evaluated ORR (by mRECIST), PFS and OS.24 Median age was 732 years (range 52-92), and 558 (74%) were male. Three patients received immunotherapy as first-line. Sixty-three Fifty-eight (78%) patients had epithelioid histology, 42 treated in second-line. PD-L1 expression was not determined in 45 patients, <1% in 16, and ≥1% in 21. Median OS of the entire population was 857.9 months, median PFS 794.2 months, ORR 256%, and DCR 71%.

The PROMISE-meso trial in 2019, results of a phase III, open-label, randomized trial PROMISE-meso trial have been presented.25 This trial randomized 1:1 MPM patients, who progressed to platinum-based chemotherapy, to receive either pembrolizumab 200 mg q3w or chemotherapy based on investigator choice (gemcitabine or vinorelbine). Histological subtype (epithelioid vs non-epithelioid) was the only stratification factor, while PD-L1 expression was
The primary end-point was PFS (assessed by blinded independent central review), and secondary end-points were ORR (by RECIST 1.1), time to treatment failure, OS, investigator-assessed PFS and adverse events. PD-L1 immunohistochemistry was assessed by using clone SP263. The study enrolled 144 patients (73 treated with pembrolizumab, 50.7%), 90.89% with epithelioid histology. 82.80% males. After a median follow-up of 11.8 months, pembrolizumab arm showed a median PFS of 2.5 months as compared to 3.4 months of the control (HR 1.06, 95% CI: 0.73-1.53, p=0.76 stratified by histological subtype). Pembrolizumab led to a superior ORR (22% vs 6%, p=0.004), while the median DoR was higher with chemotherapy (117.2 months vs 4.6 months). Median OS was not statistically different between study arms, being 10.7 and 11.47 months in the experimental and control arm, respectively (HR 1.0412, 95% CI: 0.6674-1.697, p=0.5985), without differences even after adjusting for cross-over. The DCR in the pembrolizumab group was 45%, with 16 patients achieving PR and 17 SD. No differences were observed neither in median PFS nor in OS according to PD-L1 expression (TPS <1% vs ≥1%).

A retrospective single-centre cohort study of pembrolizumab in MPM included 13 non-papillary peritoneal tumours, all pre-treated with chemotherapy. Median age of enrolled patients was 65.6 years, 62% had known asbestos exposure. Histology was epithelioid in 70% of cases. ORR was 18%, while DCR was 81%. Median PFS and OS were 5.7 and 20.9 months, respectively. No differences in PFS were observed comparing epithelioid histology vs others, or by PD-L1 status (positive vs negative, median PFS 5.1 vs 5.7 months respectively, p=0.73).

Another retrospective real-world study included 98 patients with MM (95 pleural, 3 peritoneal) treated with pembrolizumab. Median age was 70 years (range 46-91), most patients were male (92%) and with ECOG-PS of 0-1 (78%), 76% had epithelioid histology. Four patients received pembrolizumab as first-line because unfit for chemotherapy, while the others were chemotherapy pre-treated (64% one previous line). Pembrolizumab was administered at 200 mg q3w (73%) or at 2 mg/Kg q3w (27%), the median number of cycles was 6 (range 1-35). PD-L1 was assessed with. Using a 1% cut-off, PD-L1 expression (E1L3N clone) resulted negative in 46%, positive in 32%, while for remaining data was missing. ORR was 18% (95% CI: 12-28%) as per investigator-assessed mRECIST, and DCR 56% (95% CI: 47-66). The median PFS and OS were 4.8 (95% CI: 3.6-6.2) and 9.5 (6.6-13.7) months, respectively. PD-L1 expression and BRCA1 associated protein 1 (BAP1) loss were not associated with objective response, although ORR was numerically higher in PD-L1+ patients (23% vs 11%) and those with BAP1 loss (20% vs 13%).
Kim et al evaluated 115 patients treated with pembrolizumab, nivolumab, or nivolumab in combination with ipilimumab after disease progression to first-line platinum-based chemotherapy. The median age was 75 years (IQR 69-79.5), most were male (74%), and had epithelioid histology (67%). The median OS of the entire cohort was 8.7 months (95% CI: 7.7-10.9).

Finally, 1184 patients with ECOG PS 0 to 1 who had disease progression on or intolerance to standard therapy affected by asMM were enrolled into the MPM cohort of Keynote-158 trial, a phase 2 single-arm study assessing the efficacy of pembrolizumab in patients with non-colorectal high microsatellite instability/mismatch repair deficient tumours. The median age was 68 years (IQR 61-64), 69% (n=82) had epithelioid histology, 48% (n=57) received immunotherapy as second-line; 77 out of 108 assessable tumours had positive PD-L1 expression (>1 by 22C3 clone). Among 233 enrolled patients, ORR was 34.3% (95% CI: 28.3-40.8), median DoR was 14.3 months, and the median PFS and OS were 4.12 (95% CI: 2.14-4.3) and 23.3 (95% CI: 13.6-not reached) months, respectively. However, data about patients with asMM are not available. ORR in PD-L1 positive patients was 12%.

3.2 Meta-analysis

We selected 130 studies including 487,888 patients, most with pleural MM. Table 1 summarizes the main characteristics of the selected trials. Four studies were excluded due to the inclusion of treatment naïve patients, while one study because no data on asMM patients were available, and one due to the inclusion of patients treated with dual ICIs combination. The analysis of patients from the phase III PROMISE-meso and CONFIRM trials was restricted to those assigned to pembrolizumab (n=73) immunotherapy. Data on responses were available for 487,888 patients, irrespective of PD-L1 levels. A total of 434,835 patients (89.19%) received anti-PD-1 inhibitors (nivolumab [4] or pembrolizumab [4]), while 53 (10.81%) were treated with avelumab (A). Table 1. In aggregate, ORR was 20.118.1% (95% CI: 16.813.9-22.027.8%, Cochran’s Q p=0.0011, I²=63.35%) with no significant differences between drugs (N: 21.5%, P: 21.4%, A: 9.4%, p=0.121, I²=26.48%, p=0.2027) (Figure 2). DCR was 5455.46% (95% CI: 50.248.1-59.62.59%) without significant differences between agents (N: 51.7%, P: 57.8%, A: 58.5%, p=0.385, I²=68.14%, Cochran’s Q p=0.00019, I²=76.57%) (Figure 3). In unselected patients, the median PFS ranged from 2.15 to 6.15 months, while the median OS from 6.7 to 20.9 months.
Tumour response according to PD-L1 expression were reported in 106 out of 10.13 studies, with PD-L1 positivity defined using heterogeneous cut-offs depending of each different trial (ranging from 1% to 50%).9,12,13,15,20,23 This subgroup included 125-304 and 131-310 patients, depending on the clone adopted in the study by Scherpereel et al. (n: 125 for the 28-8, n: 131 for the SP-263, respectively) (Table 2).15 ORR was 34.428.0% (95% CI: 26.719.0-43.138.0%) and 32.227.0% (95% CI: 24.187.7-36.240.5%, respectively). In different studies [Figure 4], forest plot of the analysis with the largest sample, accounting for the use of SP-263 clone in 15; accounting for the use of 28-8 clone). No publication biases were found at a significance level < 0.05. The funnel plots showed no evidence of publication bias [Figure 5, Figure 6, Figure 7, s Figure 2]. [Figure 4, Figure 5].

4. Discussion

The present study performed a systematic review and meta-analysis to evaluate the activity of anti-PD-1/PD-L1 in pre-treated asMM in terms of ORR and DCR. Notably, as higher efficacy is observed in tumours whose aetiology is associated to carcinogens exposure. ICI evaluation in asMM finds a rational as most cases are related to asbestos exposure. Therefore, the assessment of the efficacy of ICI in asMM finds a rationale as most of the cases are related to asbestos exposure. Unfortunately, most of the studies about ICIs in asMM do not report this information. At the same time, MM is partially somehow resistant to cytotoxic chemotherapy, especially non-epithelioid subtypes. The recent demonstration that the combination of the anti-CTLA-4 monoclonal antibody ipilimumab with nivolumab could significantly increase OS as compared to platinum plus pemetrexed in the first-line setting, is predicted to change the treatment landscape of this aggressive disease. However, while the superiority of ICIs combination appeared to be clear in non-epithelioid tumors, patients with epithelioid MM showed less benefit and chemotherapy may be still regarded as a treatment option, while waiting for the results of chemo-immunotherapy combination from ongoing clinical trials. Unfortunately, due to the lack of specific data, we could not evaluate the activity of ICIs in pre-treated patients according to histology, and assessing platinum-based chemotherapy, second-line treatments have never formally demonstrated to increase survival as compared to best supportive care have only modest efficacy. Indeed, international guidelines suggest the treatment with vinorelbine or gemcitabine in pre-treated patients, reporting...
ORR of 8.63%, a DCR of 54.8%, and a median PFS and OS of 3.4 and 7.86 months, respectively. Only recently a formal demonstration of vinorelbine efficacy has been provided by a phase 2 trial. Moreover, another randomised phase 2 trial showed that the addition of the anti-vascular endothelial growth factor receptor 2 (VEGFR-2) monoclonal antibody ramucirumab to gemcitabine could increase OS as compared to gemcitabine and placebo in second-line setting.

Our present meta-analysis indicates that ICIs provide an ORR and DCR of 20% and 55%, respectively, without significant differences between agents. Overall, the heterogeneity between the studies was low-moderate when evaluating the ORR, both in the entire population and in patients whose tumours expressed PD-L1, while the heterogeneity was significant for the evaluation of the DCR. We did not found any significant evidence of publication bias.

However, the results of the phase 3 PROMISE-meso trial showed that, despite the higher ORR with pembrolizumab, no survival differences were observed as compared to single agent chemotherapy in pre-treated advanced-stage MM. Notably, this trial was designed with PFS as primary end-point. OS events were at the time of the analysis, leading to a 196% statistical power for a HR of 0.8, meaning that the study was not powered to allow meaningful conclusion about OS. Indeed, the interpretation of these results is challenging. Since most of the studies included in our meta-analysis lack of a comparison arm, we were not capable to compare ICIs with single-agent chemotherapy. However, to our knowledge, ORR has never been demonstrated to be a surrogate marker of survival in MM. Moreover, the selected trials have used different criteria for response evaluation such as mRECIST and iRECIST, and some of the considered cases did not have independent assessment. For this latter reason, as most studies were single-arm trials, observer bias could not be ruled out.

The present meta-analysis suggests that PD-L1+ tumours might better respond to single-agent immunotherapy. However, trials are highly heterogeneous when accounting for PD-L1 evaluation because different IHC clones and cut-offs were used, so that these data should be taken with caution. Indeed, available data suggest that PD-L1 expression in malignant pleural mesothelioma is prognostic, with high levels associated with poorer outcomes even after accounting for other variables such as histology and performance status. Moreover, a recent publication reported that the antigenic potential of mesothelioma could be better predicted by other factors, including chromosomal rearrangements (chromoplexy and chromothripsis). Such interesting data deserve more studies in the context of ICIs therapy for
Adoptive immunotherapy as well as vaccines, alone or in combination with ICIs, are another active field of investigation. Preliminary results of a phase I study of intrapleural injection of mesothelin-targeted chimeric antigen receptor T-cell (CAR-T) therapy, with or without anti PD-1 agents, showed 63% RR in 18 asMM patients, 37% of which already treated with 3 or more lines of therapy. The treatment landscape of asMM is therefore expected to change, and immunotherapy may have a pivotal role both in treatment-naïve and pre-treated patients. Along with those from Checkmate 743, results of ongoing studies on chemo-immunotherapy combinations are. The recent results of the Checkmate 743 trial, showing that nivolumab plus ipilimumab led to significantly longer OS as compared to platinum plus pemetrexed in untreated unresectable MPM, are starting this paradigm shift are expected to change the treatment landscape of untreated unresectable MPM. While waiting for these data, Non-epithelioid tumours seem to derive the most benefit. Unfortunately, due to the lack of specific data, we could not evaluate the activity of single-agent ICIs in different histologies. As results of other ongoing studies are eagerly awaited, our meta-analysis suggests that anti-PD-(L)1 agents might be useful in some chemotherapy pre-treated patients, even if reliable predictive factors are still lacking.
Figure legends

Figure 1. PRISMA flowchart of selected trials

Figure 2. Objective response rate of trials selected for the meta-analysis and aggregate data

Abbreviations. ORR: objective response rate.

Figure 3. Disease control rate of trials selected for the meta-analysis and aggregate data

Figure 4. Objective response rate of trials reporting activity according to PD-L1 expression and aggregate data.


Figure 5. Funnel plot for objective response rate

Figure 6. Funnel plot for disease control rate

Figure 7. Funnel plot for objective response rate in PD-L1 positive patients (Scherpereel SP-263)

tFigure 1. Objective response rate of trials reporting activity according to PD-L1 expression and aggregate data (Scherpereel 28-8)

tFigure 2. Funnel plot for objective response rate in PD-L1 positive patients (Scherpereel 28-8)
REFERENCES


Table 1. Main characteristics of trials selected for the meta-analysis

<table>
<thead>
<tr>
<th>Study</th>
<th>Phase</th>
<th>Setting</th>
<th>Population (subtypes)</th>
<th>Drug</th>
<th>ORR a % (n)</th>
<th>DCR a % (n)</th>
<th>Median OS a months (95% CI)</th>
<th>Median PFS a months (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hassan et al. JAMA Oncol 2019</td>
<td>Ib</td>
<td>Pts progressed after platinum and pemetrexed</td>
<td>53</td>
<td>Avelumab 10 mg/kg every two weeks</td>
<td>9 (5/53)</td>
<td>58 (31/53)</td>
<td>10.7 (6.4-20.2)</td>
<td>4.1 (1.4-6.2)</td>
</tr>
<tr>
<td>Quispel-Janssen et al. JTO 2018</td>
<td>II</td>
<td>Pts progressed after at least one CT regimen</td>
<td>34</td>
<td>Nivolumab 3 mg/kg every two weeks</td>
<td>26 (9/34)</td>
<td>47 (16/34)</td>
<td>11.8 (9.7-15.7)</td>
<td>2.6 (2.23-5.49)</td>
</tr>
<tr>
<td>Okada et al. Clin Cancer Res 2019</td>
<td>II</td>
<td>Pts resistant to maximum 2 regimens of CT including platinum-pemetrexed</td>
<td>34</td>
<td>Nivolumab 240 mg every two weeks</td>
<td>29 (10/34)</td>
<td>68 (23/34)</td>
<td>17.3 (11.5-NR)</td>
<td>6.1 (2.9-9.9)</td>
</tr>
<tr>
<td>Scherpereel et al. Lancet Oncol 2019</td>
<td>II</td>
<td>Pts progressed after first-or second-line platinum-pemetrexed CT</td>
<td>63</td>
<td>Nivolumab 3 mg/kg every two weeks</td>
<td>17 (11/63)</td>
<td>40 b (25/63)</td>
<td>11.9 (6.7-17.7)</td>
<td>4 (2.8-5.7)</td>
</tr>
<tr>
<td>Dumoulin et al. JTO 2019</td>
<td>Real-world</td>
<td>Pts progressed after at least one cycle of platinum-folate CT</td>
<td>59</td>
<td>Nivolumab 3 mg/kg every two weeks</td>
<td>12 (7/59)</td>
<td>41 (24/59)</td>
<td>6.36 (4.92-9.12)</td>
<td>2.64 (1.56-4.20)</td>
</tr>
<tr>
<td>Mikami et al. JCO 2020</td>
<td>Retrospective single-centre</td>
<td>Pts pretreated with at least one line of therapy</td>
<td>79</td>
<td>Nivolumab</td>
<td>27 (19/71)</td>
<td>66 (47/71)</td>
<td>14.3 (9.4-NR)</td>
<td>4.1 (3.4-7-5)</td>
</tr>
<tr>
<td>Alley et al.</td>
<td>Ib</td>
<td>Pts for whom standard</td>
<td>25</td>
<td>Pembrolizumab 10 mg/kg every 2 weeks</td>
<td>20 (5/25)</td>
<td>72 (18/25)</td>
<td>18 (9.4-NR)</td>
<td>5.4 (3.4-7-5)</td>
</tr>
<tr>
<td>Study</td>
<td>Stu &lt;br&gt;dy &lt;br&gt;Phase</td>
<td>Patients &lt;br&gt;Characteristics</td>
<td>Therapy &lt;br&gt;Characteristics</td>
<td>ORR &lt;br&gt;95% CI</td>
<td>DCR &lt;br&gt;95% CI</td>
<td>OS (months)</td>
<td>PFS (months)</td>
<td></td>
</tr>
<tr>
<td>-------------------------------</td>
<td>-----------------------</td>
<td>---------------------------------------------------------------------------------------------</td>
<td>------------------------------</td>
<td>----------------</td>
<td>---------------</td>
<td>-------------</td>
<td>-------------</td>
<td></td>
</tr>
<tr>
<td>Desai et al. JTO 2018</td>
<td>II</td>
<td>Pts progressed after platinum-pemetrexed, who received no more than two lines of therapy</td>
<td>Pembrolizumab b 200 mg every 3 weeks</td>
<td>22 (14/64)</td>
<td>63 (40/64)</td>
<td>11.5 (na)</td>
<td>4.1 (na)</td>
<td></td>
</tr>
<tr>
<td>Popat et al. Ann Oncol 2019</td>
<td>III</td>
<td>Pts progressed after previous platinum-based CT</td>
<td>Pembrolizumab b 200 mg every 3 weeks</td>
<td>22 (16/73) e</td>
<td>45 (33/73)</td>
<td>10.7 (7.6-ne)</td>
<td>2.5 (2.1-4.2)</td>
<td></td>
</tr>
<tr>
<td>Marmareli s et al. JCO 2020</td>
<td>Retrospective single-centre</td>
<td>Pts progressed to a previous CT</td>
<td>Pembrolizumab b</td>
<td>18 (2/11)</td>
<td>81 (9/11)</td>
<td>20.9 (na)</td>
<td>5.7 (na)</td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations.** ORR: objective response rate; DCR: disease control rate; OS: overall survival; PFS: progression-free-survival; Pts: patients; CI: interval confidence; CT: chemotherapy; NR: not reached; ne: not estimable; na: not available

a Calculated among patients evaluable for disease response or outcomes  
b DCR at 12 weeks from randomization  
c Pembrolizumab cohort
### Table 2. Main characteristic of trials reporting activity according to PD-L1 expression

<table>
<thead>
<tr>
<th>Study</th>
<th>PD-L1 threshold</th>
<th>IHC PD-L1 antibody clone</th>
<th>Population evaluable for PD-L1 (PD-L1 positive pts)</th>
<th>ORR in PD-L1 positive pts % (n)</th>
<th>Median OS in PD-L1 positive pts months (95% CI)</th>
<th>Median PFS in PD-L1 positive pts months (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hassan et al. JAMA Oncol 2019</td>
<td>5%</td>
<td>73-10</td>
<td>43 (16)</td>
<td>19 (3/16)</td>
<td>20.2 (4.9-ne)</td>
<td>5.3 (1.4-17.8)</td>
</tr>
<tr>
<td>Quispel-Janssen et al. JTO 2018</td>
<td>1%</td>
<td>28-8</td>
<td>33 (9)</td>
<td>56 (5/9)</td>
<td>na</td>
<td>na</td>
</tr>
<tr>
<td>Okada et al. Clin Cancer Res 2019</td>
<td>1%</td>
<td>28-8</td>
<td>32 (20)</td>
<td>40 (8/20)</td>
<td>ne (HR OS 0.542; 95% CI 0.208-1.415)</td>
<td>ne (HR 0.725; 95% CI 0.316-1.668)</td>
</tr>
<tr>
<td>Scherpereel et al. Lancet Oncol 2019</td>
<td>1%</td>
<td>28-8</td>
<td>99</td>
<td>39 (16/41)</td>
<td>na</td>
<td>na</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SP-263</td>
<td>104</td>
<td>32 (15/47)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alley et al. Lancet Oncol 2017</td>
<td>1%</td>
<td>22C3</td>
<td>25</td>
<td>20 (5/25)</td>
<td>18 (9.4-NR)</td>
<td>5.4 (3.4-7-5)</td>
</tr>
<tr>
<td>Desai et al. JTO 2019</td>
<td>50%</td>
<td>22C3</td>
<td>62 (14)</td>
<td>43 (6/14)</td>
<td>12.5</td>
<td>4.9</td>
</tr>
<tr>
<td>Popat et al. Ann Oncol 2019</td>
<td>1%</td>
<td>E1I3N</td>
<td>51 (32)</td>
<td>na</td>
<td>10.7 (6.8-ne)</td>
<td>3.2 (1.9-4.2)</td>
</tr>
</tbody>
</table>

**Abbreviations.** IHC: immunohistochemistry; PD-L1: programmed death-ligand 1; ORR: objective response rate; OS: overall survival; PFS: progression-free-survival; CI: interval confidence; HR: hazard ratio; ne: not estimable, na: not available.
**Table 1.** Main characteristics of trials selected for the meta-analysis

<table>
<thead>
<tr>
<th>Study</th>
<th>Phase</th>
<th>Setting</th>
<th>Population (subtypes)</th>
<th>Drug</th>
<th>ORR  a % (n)</th>
<th>DCR  a % (n)</th>
<th>Median OS a months (95% CI)</th>
<th>Median PFS a months (95% CI)</th>
<th>Median PFS and OS by histology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hassan et al. JAMA Oncol 2019</td>
<td>Phase Ib</td>
<td>Pts progressed after platinum and pemetrexed</td>
<td>53</td>
<td>Avelumab 10 mg/kg every two weeks</td>
<td>9 (5/53)</td>
<td>58 (31/53)</td>
<td>10.7 (6.4-20.2)</td>
<td>4.1 (1.4-6.2)</td>
<td>na</td>
</tr>
<tr>
<td>Quispel-Janssen et al. JTO 2018</td>
<td>Phase II</td>
<td>Pts progressed after at least one CT regimen</td>
<td>34</td>
<td>Nivolumab 3 mg/kg every two weeks</td>
<td>26 (9/34)</td>
<td>47 (16/34)</td>
<td>11.8 (9.7-15.7)</td>
<td>2.6 (2.23-5.49)</td>
<td>na</td>
</tr>
<tr>
<td>Fujimoto et al. JTO Clin and Research Reports 2021</td>
<td>Phase II</td>
<td>Pts resistant to maximum 2 regimens of CT including platinum-pemetrexed</td>
<td>34</td>
<td>Nivolumab 240 mg/kg every two weeks</td>
<td>29 (10/34)</td>
<td>68 (23/34)</td>
<td>17.3 (11.5-26.6)</td>
<td>5.9 (na)</td>
<td>Ep vs non-Ep mOS 15.7 vs 26.6 months (HR 2.10, 95% CI 0.73-6.11) mPFS 3.9 vs 18.2 months (HR 2.79, 95% CI 1.03-7.56)</td>
</tr>
<tr>
<td>Scherpere 1 et al.</td>
<td>Phase II</td>
<td>Pts progressed after first- or second-line</td>
<td>63 b Epithelioid 52</td>
<td>Nivolumab 3 mg/kg every two weeks</td>
<td>17 (11/63)</td>
<td>40 (25/63)</td>
<td>11.9 (6.7-17.7)</td>
<td>4 (2.8-5.7)</td>
<td>ne</td>
</tr>
<tr>
<td>Study</td>
<td>Design</td>
<td>Population Description</td>
<td>Pts progressed after at least one cycle of platinum-pemetrexed CT</td>
<td>Nivolumab 3 mg/kg every two weeks</td>
<td>Nivolumab 240 mg every two weeks (vs placebo)</td>
<td>Non-Ep vs Ep mOS</td>
<td>Pts pretreated with at least one line of therapy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------------------------</td>
<td>----------------------------------</td>
<td>----------------------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------</td>
<td>-----------------------------------</td>
<td>-----------------------------------------------</td>
<td>-----------------</td>
<td>-------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cantini et al. TLCR 2020</td>
<td>Real-world (expanded access program)</td>
<td>Pts progressed after at least one cycle of platinum-folate CT</td>
<td>107 Epithelioid 78 Sarcomatoid or mixed 22 Unknown 7</td>
<td>10 (11/107)</td>
<td>37 (40/107)</td>
<td>6.7 (6.2-10.0)</td>
<td>2.3 (1.6-2.9)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mikami et al. JCO 2020</td>
<td>Retrospective single-centre</td>
<td>Pts pretreated with at least one line of therapy</td>
<td>79 Epithelioid 64 Sarcomatoid 9 Biphasic 6</td>
<td>Nivolumab</td>
<td>27 (19/71)</td>
<td>14.3 (14.3)</td>
<td>4.1 (na)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fennell et al. Lancet Oncol 2021</td>
<td>Phase III</td>
<td>Pts progressed after/on platinum-based CT</td>
<td>221 Epithelioid 195 Non-Epithelioid 26</td>
<td>Nivolumab 240 mg every two weeks (vs placebo)</td>
<td>11 (25/221)</td>
<td>10.2 (8.5–12.1)</td>
<td>3.0 (2.8-4.1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alley et al. JTO 2017</td>
<td>Phase Ib</td>
<td>Pts for whom standard therapy failed</td>
<td>25 Epithelioid 18 Sarcomatoid 2 Biphasic 2 Unknown 3</td>
<td>Pembrolizumab 10 mg/kg every 2 weeks</td>
<td>28 (7/25)</td>
<td>18 (9.4-NR)</td>
<td>5.8 (3.4-8.2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Desai et al. JTO 2018</td>
<td>Phase II</td>
<td>Pts progressed after platinum-pemetrexed, who received no more than 64</td>
<td>Pembrolizumab 200 mg every 3 weeks</td>
<td>Pembrolizumab 200 mg every 3 weeks</td>
<td>22 (14/64)</td>
<td>11.5 (na)</td>
<td>4.1 (na)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study</td>
<td>Study Type</td>
<td>Therapies</td>
<td>Patients Progressed to Previous CT</td>
<td>Therapy</td>
<td>Pembrolizumab Doses</td>
<td>Pembrolizumab (d)</td>
<td>Pembrolizumab PFS (mo)</td>
<td>Pembrolizumab OS (mo)</td>
<td>Ep vs non-Ep OS (mo)</td>
</tr>
<tr>
<td>-----------------------</td>
<td>-----------------------------</td>
<td>-----------------------------------------------</td>
<td>------------------------------------</td>
<td>---------</td>
<td>---------------------</td>
<td>-------------------</td>
<td>------------------------</td>
<td>-----------------------</td>
<td>----------------------</td>
</tr>
<tr>
<td>Marmareli et al. JCO 2020</td>
<td>Retrospective, single-centre</td>
<td>two lines of therapy</td>
<td>Pts progressed to a previous CT</td>
<td>13 Epithelioid 9 Sarcomatoid 2 Biphasic 1 Desmoplastic 1</td>
<td>Pembrolizumab</td>
<td>18 (2/11)</td>
<td>81 (9/11)</td>
<td>20.9 (na)</td>
<td>5.7 (na)</td>
</tr>
<tr>
<td>Popat et al. Ann Oncol 2020</td>
<td>Phase III</td>
<td>Pts progressed after/on platinum-based CT</td>
<td>73 d Epithelioid 66 Non-Epithelioid 7</td>
<td>Pembrolizumab 200 mg every 3 weeks (vs monotherapy)</td>
<td>22 (16/73)</td>
<td>45 (33/73)</td>
<td>10.7 (7.6–15.0)</td>
<td>2.5 (2.1–4.2)</td>
<td>ne</td>
</tr>
<tr>
<td>Yap et al. Lancet Respir Med 2021</td>
<td>Phase II</td>
<td>Pts progressed or ineligible to standard therapies</td>
<td>118 Epithelioid 82 Sarcomatoid 9 Biphasic 10 na 17</td>
<td>Pembrolizumab 200 mg every 3 weeks</td>
<td>8 (10/118)</td>
<td>46 (54/118)</td>
<td>10.0 (7.6–13.4)</td>
<td>2.1 (2.1–3.9)</td>
<td>na</td>
</tr>
<tr>
<td>Zhou et al. Clinical Lung Cancer 2021</td>
<td>Retrospective, single-centre</td>
<td>Pts pretreated with at least one line of therapy</td>
<td>14 Epithelioid 13 Mixed 1 Pembrolizumab (n=12), nivolumab (n=2)</td>
<td>Pembrolizumab (n=12), nivolumab (n=2)</td>
<td>21 (3/14)</td>
<td>43 (6/14)</td>
<td>na</td>
<td>na</td>
<td>na</td>
</tr>
</tbody>
</table>

**Abbreviations.** ORR: objective response rate; DCR: disease control rate; OS: overall survival; PFS: progression-free-survival; Pts: patients; CI: interval confidence; CT: chemotherapy; NR: not reached; ne: not estimable; na: not available; Ep: epithelioid; non-Ep: non-epithelioid; iv: intravenous.
a Calculated among patients evaluable for disease response or outcomes
b Nivolumab cohort
c DCR at 12 weeks from randomization
d Pembrolizumab cohort
### Table 2. Main characteristic of trials reporting activity according to PD-L1 expression

<table>
<thead>
<tr>
<th>Study</th>
<th>PD-L1 threshold</th>
<th>IHC PD-L1 antibody clone</th>
<th>Population evaluable for PD-L1 (PD-L1 positive pts)</th>
<th>ORR in PD-L1 positive pts % (n)</th>
<th>Median OS in PD-L1 positive pts months (95% CI)</th>
<th>Median PFS in PD-L1 positive pts months (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hassan et al. JAMA Oncol 2019</td>
<td>5%</td>
<td>73-10</td>
<td>43 (16)</td>
<td>19 (3/16)</td>
<td>20.2 (4.9-ne)</td>
<td>5.3 (1.4-17.8)</td>
</tr>
<tr>
<td>Quispel-Janssen et al. JTO 2018</td>
<td>1%</td>
<td>28-8</td>
<td>33 (9)</td>
<td>56 (5/9)</td>
<td>na</td>
<td>na</td>
</tr>
<tr>
<td>Fujimoto et al. JTO Clin and Res Reports</td>
<td>1%</td>
<td>28-8</td>
<td>32 (20)</td>
<td>40 (8/20)</td>
<td>19.1 (ne)</td>
<td>7.2 (ne)</td>
</tr>
<tr>
<td>Scherpereel et al. Lancet Oncol 2019</td>
<td>1%</td>
<td>28-8</td>
<td>99</td>
<td>39 (16/41)</td>
<td>na</td>
<td>na</td>
</tr>
<tr>
<td>SP-263</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cantini et al. TLCR 2020</td>
<td>1%</td>
<td>SP263 or 22C3</td>
<td>33 (11)</td>
<td>36 (4/11)</td>
<td>5.4 (ne)</td>
<td>4.2 (ne)</td>
</tr>
<tr>
<td>Fennel et al. Lancet Oncol 2021</td>
<td>1%</td>
<td>22C3</td>
<td>161 (60) a</td>
<td>12 (7/60) b</td>
<td>na</td>
<td>na</td>
</tr>
<tr>
<td>Alley et al. Lancet Oncol 2017</td>
<td>1%</td>
<td>22C3</td>
<td>25</td>
<td>20 (5/25)</td>
<td>18 (9.4-NR)</td>
<td>5.4 (3.4-7-5)</td>
</tr>
<tr>
<td>Desai et al. JTO 2019</td>
<td>50%</td>
<td>22C3</td>
<td>62 (14)</td>
<td>43 (6/14)</td>
<td>12.5</td>
<td>4.9</td>
</tr>
<tr>
<td>Popat et al. Ann Oncol 2020</td>
<td>1%</td>
<td>E1L3N</td>
<td>69 (31) b</td>
<td>29 (9/31) a</td>
<td>13.8 a (7.5-NR)</td>
<td>4.1 a (1.9-4.3)</td>
</tr>
<tr>
<td>Yap et al. Lancet Respir Med 2021</td>
<td>1%</td>
<td>22C3</td>
<td>108 (77)</td>
<td>12 (9/77)</td>
<td>na</td>
<td>na</td>
</tr>
</tbody>
</table>

**Abbreviations.** IHC: immunohistochemistry; PD-L1: programmed death-ligand 1; ORR: objective response rate; OS: overall survival; PFS: progression-free-survival; CI: interval confidence; HR: hazard ratio; ne: not estimable; na: not available; NR: not reached.

a Pembrolizumab cohort
b Nivolumab cohort
947 potentially relevant studies

- 912 primarily excluded (reviews, editorials, case reports, non-interventional studies)
- 35 potentially relevant studies
  - 22 excluded (trial design report only, combination trials, first-line trials, not in English)
  - 15 studies with single-agent PD-1/PD-L1 inhibitors
    - 3 excluded due to the inclusion of treatment-naïve patients, 1 after multi-modality treatment, 1 different drug dosages, 1 lack of data on aMM patients

1 relevant paper from International Meeting

10 studies selected for the analysis
Figure 7

Click here to access/download;Figure;Figure 7 ORR PDL1 funnel plot (Scherpereel SP-263).pptx
973 studies

52 potentially relevant studies

37 excluded (trial design report only, combination trials, first-line trials, not in English)

921 primarily excluded (reviews, editorials, case reports, non interventional studies)

15 studies with single-agent PD-1/PD-L1 inhibitors

3 relevant studies from International Meetings

13 studies selected for the meta-analysis

4 excluded due to the inclusion of treatment-naïve patients, 1 due to the inclusion of patients treated with immunotherapy doublet and not reporting the response rate
Figure 2

Proportion
Alley 2017
Desai 2018
Quispel-Janssen 2018
Scherpereel 2019
Hassan 2019
Marmarelis 2020
Cantini 2020
Popat 2020
Mikami 2020
Fujimoto 2021
Fennel 2021
Yap 2021
Zhou 2021
Total (fixed effects)
Total (random effects)

Proportion
0.0 0.1 0.2 0.3 0.4 0.5 0.6

Click here to access/download: Figure 2_ORR forest plot.pptx
<table>
<thead>
<tr>
<th>Study</th>
<th>Proportion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alley 2017</td>
<td></td>
</tr>
<tr>
<td>Desai 2018</td>
<td></td>
</tr>
<tr>
<td>Quispel-Janssen 2018</td>
<td></td>
</tr>
<tr>
<td>Scherpereel 2019</td>
<td></td>
</tr>
<tr>
<td>Hassan 2019</td>
<td></td>
</tr>
<tr>
<td>Marmarelis 2020</td>
<td></td>
</tr>
<tr>
<td>Cantini 2020</td>
<td></td>
</tr>
<tr>
<td>Popat 2020</td>
<td></td>
</tr>
<tr>
<td>Mikami 2020</td>
<td></td>
</tr>
<tr>
<td>Fujimoto 2021</td>
<td></td>
</tr>
<tr>
<td>Fennel 2021</td>
<td></td>
</tr>
<tr>
<td>Yap 2021</td>
<td></td>
</tr>
<tr>
<td>Zhou 2021</td>
<td></td>
</tr>
<tr>
<td>Total (fixed effects)</td>
<td></td>
</tr>
<tr>
<td>Total (random effects)</td>
<td></td>
</tr>
</tbody>
</table>
Supplementary figure 1
Highlights:

- First systematic review on single-agent immune checkpoint inhibitors (ICIs) against PD-1/PD-L1 in pre-treated advanced malignant mesothelioma
- Single-agent ICIs could lead to 18.1% response rate and 55.4% disease-control rate in pre-treated advanced malignant mesothelioma
- This result compares favourably with historical data with single-agent chemotherapy
- Predictive factors of immunotherapy efficacy are still lacking
Highlights:

- First systematic review on single-agent immune checkpoint inhibitors (ICIs) against PD-1/PD-L1 in pre-treated advanced malignant mesothelioma
- Single-agent ICIs could lead to 18.1% response rate and 55.4% disease-control rate in pre-treated advanced malignant mesothelioma
- This result compares favourably with historical data with single-agent chemotherapy
- Predictive factors of immunotherapy efficacy are still lacking
A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma

947 potentially relevant studies
35 potentially relevant studies
15 studies with single-agent PD-1/PD-L1 inhibitors

912 primarily excluded (reviews, editorials, case reports, non interventional studies)
22 excluded (trial design report only, combination trials, first-line trials, not in English)

497 patients with chemotherapy-pretreated advanced stage malignant mesothelioma
487 evaluable for disease response
434 treated with anti-PD-1 nivolumab or pembrolizumab
53 treated with anti-PD-L1 avelumab

121 and 135 patients* selected according to PD-L1 expression and evaluable for disease response

Objective response rate
20.1% (95% CI: 16.8 - 23.9%)
No significant differences between drugs
(nivolumab 21.5%, pembrolizumab 21.4%, avelumab 9.4%; p=0.121)

Disease control rate
54.6% (95% CI: 50.2 - 59.0%)
No significant differences between agents
(nivolumab 51.7%, pembrolizumab 57.8%, avelumab 58.5%; p=0.385)

PD-L1 positive tumors
Objective response rate*
34.4% (95% CI: 26.7 - 43.1%) and
32.1% (95% CI: 24.7 - 40.5%)

* Number of patients based on the use of PD-L1 IHC clone 28-8 or SP-263, respectively, in the study by Schepereel et al.

* Patient selected according to the highest threshold of PD-L1 expression in each study.
A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma

3 relevant studies from International Meetings

13 studies selected for analyses, fulfilling inclusion criteria

888 patients with pretreated advanced stage malignant mesothelioma

- 835 treated with anti-PD-1 nivolumab or pembrolizumab
- 53 treated with anti-PD-L1 avelumab

304 and 310 patients* selected according to PD-L1 expression and evaluable for disease response

Objective response rate
18.1% (95% CI: 13.9 - 22.8%)

Disease control rate
55.4% (95% CI: 48.1 - 62.5%)

PD-L1 positive tumors°
Objective response rate*
28.0% (95% CI: 19.0 - 38.0%) and
27.0% (95% CI: 18.7 - 36.2%)

* Number of patients based on the use of PD-L1 IHC clone 28-8 or SP-263, respectively, in the study by Scherpereel et al.

* Patient selected according to the highest threshold of PD-L1 expression in each study

973 potentially relevant studies

52 potentially relevant studies

18 studies with single-agent PD-1/PD-L1 inhibitors

921 primarily excluded (reviews, editorials, case reports, non-interventional studies)

37 excluded (trial design report only, combination trials, first-line trials, not in English)
Acknowledgements

The Authors did not receive any funding for this original work.
Conflict of interest statement

Marco Tagliamento declares travel, accommodations, expenses supported by Roche, Bristol-Myers Squibb, Astra Zeneca, Takeda, and activity as medical writer supported by Novartis, Amgen outside the submitted work.

Paolo Bironzo declares honoraria as speaker bureau by Roche, Bristol-Myers Squibb, Astra Zeneca, Takeda, Merck Sharp and Dohme, Beigene, outside the submitted work. He declares expenses by Amgen and Daiichi Sankyo.

Massimo Di Maio acted as consultant for Eisai, Takeda, Janssen, Astellas, Pfizer and AstraZeneca, outside the submitted work.

Giorgio Vittorio Scagliotti received honoraria from AstraZeneca, Eli Lilly, MSD, Pfizer, Roche; acts as a consultant or advisor for AstraZeneca, Beigene and Verastem; received research funding from Eli Lilly (institutional), MSD (institutional) and Tesaro (institutional); Travel, Accommodations, Expenses from Bayer.

The other Authors do not have conflict of interests to declare related to the present work.
Conflict of interest statement

Marco Tagliamento declares travel, accommodations, expenses supported by Roche, Bristol-Myers Squibb, Astra Zeneca, Takeda, and activity as medical writer supported by Novartis, Amgen outside the submitted work.

Paolo Bironzo declares honoraria as speaker bureau by Roche, Bristol-Myers Squibb, Astra Zeneca, Takeda, Merck Sharp and Dohme, Beigene, outside the submitted work. He declares expenses by Amgen and Daiichi Sankyo.

Massimo Di Maio acted as consultant for Eisai, Takeda, Janssen, Astellas, Pfizer and AstraZeneca, outside the submitted work.

Giorgio Vittorio Scagliotti received honoraria from AstraZeneca, Eli Lilly, MSD, Pfizer, Roche; acts as a consultant or advisor for AstraZeneca, Beigene and Verastem; received research funding from Eli Lilly (institutional), MSD (institutional) and Tesaro (institutional); Travel, Accommodations, Expenses from Bayer.

The other Authors do not have conflict of interests to declare related to the present work.